Doctor of Philosophy by Wang, Jin




A dissertation submitted to the faculty of 
The University of Utah 
in partial fulfillment of the requirements for the degree of
Doctor of Philosophy
Department of Chemistry 
The University of Utah 
August 2016
Copyright © Jin Wang 2016 
All Rights Reserved
T h e  U n i v e r s i t y  o f  U t a h  G r a d u a t e  S c h o o l
STATEMENT OF DISSERTATION APPROVAL
The dissertation of Jin Wang
























Cynthia Burrows , Chair/Dean of
Chemistry
and by David B. Kieda, Dean of The Graduate School.
ABSTRACT
A series of acceptor-acceptor type diazo phosphonates were successfully 
synthesized. When exposed to Rh2(OAc)4, depending on their substitution 
patterns, vinyl diazo phosphonates underwent either sulfonium ylide 
rearrangements or C-H insertion reactions to provide C-3 quaternary indolines or 
cyclopentenes, respectively. Diazo vinyl phosphonates, on the other hand, 
reacted with alcohols, amines and thiols in the presence of a Rh catalyst to 
generate vinyl ethers, enamines and vinyl sulfides. Intramolecular cyclization of 
the resulting vinyl ethers led to the formation of oxetanes and furans. This O-H 
insertion/ intramolecular cyclization strategy was utilized in the synthesis of the 
phosphonate analog of dysiherbaine.
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CHAPTER 1
INTRODUCTION
1.1 Metal carbenoids: a general introduction
Diazo compounds are powerful and versatile intermediates in synthetic 
chemistry because highly reactive carbenes can be formed by the loss of 
dinitrogen. Compared to free carbenes 1.1 generated thermally or 
photochemically, metal carbenoids 1.3 generated from metal salts and diazo 
compounds 1.2 are generally much more selective and efficient when reacting 
with nucleophiles (Scheme 1.1).1 In addition, usually only a catalytic amount of 
metal salt is needed. A number of synthetically unique transformations such as 
cyclopropanations, X-H (X = O, N, S, etc.) insertions, C-H insertions and ylide 
formations can be accomplished when treating the metal carbenoids with 
different nucleophiles.2
r  thermal or




free carbene diazo compound
1.3
metal carbenoid
Scheme 1.1 Free carbene vs metal carbenoid
The earliest catalysts applied to diazo decomposition were copper salts.3 
Although copper bronze, copper(I) and copper(II) salts can all be used as 
catalysts for this reaction, it is now established that copper(I) species are the 
active catalysts during the reaction.4 However, it was not until the C4-symmetric 
dirhodium tetracarboxylate catalysts 1.4 were discovered that metal carbenoid 
chemistry experienced exponential progress (Scheme 1.2).5 Compared to the 
traditional copper catalysts, the dirhodium catalysts are usually more efficient in 
terms of yields. In addition, rhodium catalysts are generally more versatile 
because the electronic and steric properties of the tetracarboxylate ligands can 
be easily tuned allowing for the generation of metal carbenoids with different 
reactivity profiles.6
Numerous experiments have been carried out in order to understand the 
mechanism of catalytic diazo decomposition, metal carbenoid generation and 
subsequent reactions. It is now believed that the metal catalyst first serves as a 
Lewis acid to form the diazonium ion adduct 1.7, of which the metal center 
donates a pair of electrons back to the adjacent carbon to form the metal 
carbenoid 1.8 by the loss of the dinitrogen. The reaction of the electrophilic 
carbene moiety with an electron-rich substrate regenerates the metal catalyst 
(Scheme 1.3).7
Generally, there are three types of metal carbenoids: acceptor, acceptor- 
acceptor and donor-acceptor type metal carbenoids (Scheme 1.4).8 Because 
metal carbenoids normally display electrophilic character, acceptor and acceptor- 








Scheme 1.2 Dirhodium tetracarboxylate catalyst
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Scheme 1.3 Mechanism of catalytic diazo decomposition
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Scheme 1.4 Classification of metal carbenoids
41.2 Application of metal carbenoids in natural product synthesis 
Due to their unique reactivities, metal carbenoids have been utilized in 
natural product synthesis since the 1980s.10 Acceptor type metal carbenoids and 
acceptor-acceptor type metal carbenoids were first utilized in synthetic chemistry 
because of the availability and stability of their parent diazo compounds. Due to 
their highly electrophilic nature, these two types of metal carbenoids were mostly 
involved in intramolecular reactions.
A unique reaction for metal carbenoid is the intramolecular C-H insertion, 
which provides a five membered ring in most cases. Mechanistically, the C-H 
insertion is believed to occur through a concerted mechanism when the C-C 
bond and C-H bond form as the metal catalyst dissociates (Scheme 1.5).11
The Taber group was among the first to recognize the synthetic utility of the 
intramolecular C-H insertion reaction. During detailed experiments they 
demonstrated that high diastereoselectivity could be achieved through careful 
construction of the diazo substrate and elaborate selection of the metal catalyst. 
Their work was highlighted in the first total synthesis of alkaloid 251F (Scheme 
1.6).12 Starting from the enantiopure acetal 1.17, p-ketoester formation facilitated 
the subsequent diazo transfer reaction, and diazo ester 1.18 was formed in 73% 
yield. The key diazo decomposition step was accomplished in the presence of 
Rh2(Oct)4 and provided cyclopentane 1.19 as a single diastereomer. The newly- 
formed stereocenters were shown to have the desired configurations of the 
natural product. Further functional group manipulations allowed the cyclopentane 
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Scheme 1.5 Mechanism of intramolecular C-H insertion of metal carbenoid
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Scheme 1.6 Taber's total synthesis of alkaloid 251F
Enantioselective intramolecular C-H insertion of metal carbenoids 
experienced rapid growth in the 1990s, thanks to the discovery of efficient chiral 
rhodium catalysts including rhodium carboxylates and rhodium carboxymidates.13 
The Doyle group has developed a series of carboxymidate based dirhodium 
catalysts and utilized them to catalyze intramolecular C-H insertion of diazo 
esters. One example that illustrated the power of these transformations was the 
total synthesis of lignan lactones such as hinokinin (Scheme 1.7).14 Cinnamic 
acid based diazo ester 1.22 was exposed to chiral rhodium catalyst 1.23 to give 
the desired lactone 1.24 in high yield and ee, via an intramolecular C-H insertion. 
Lactone 1.24 was then converted to the natural product hinokinin.
Ylide chemistry is another area where metal carbenoids show great utility.15 
Because of their highly electrophilic nature, metal carbenoids tend to react with 
hetero atoms to form metal associated ylides 1.28 (Scheme 1.8). The free ylides 
1.29 are formed by the dissociation of the metal catalysts. Both the metal- 
associated ylides 1.28 and the free ylides 1.29 can serve as reactive species for 
subsequent reactions. Commonly used ylides include oxonium, iminium, 
sulfonium and carbonyl ylides 1.30 - 1.33.
The Padwa group first demonstrated that metal carbenoids could be used to 
generate cyclic carbonyl ylides. They also showed that subsequent ntramolecular 
dipole cycloadditions would result in oxabicyclic substrates. Five and six 
membered cyclic carbonyl ylides were formed in most cases due to the more 
efficient orbital overlap between the metal carbenoid and carbonyl oxygen 5 or 6- 
atom away. A beautiful application of this methodology was the synthesis
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Scheme 1.8 Generation of ylide and structures of common ylides
of aspidophytine.16 Decomposition of diazo p-ketoester 1.34 and reaction of the 
resulting metal carbenoid with the neighboring imido carbonyl gave the carbonyl 
dipole intermediate 1.38, in situ cyclization with the tethered indolyl group 
provided cycloadduct 1.35 (Scheme 1.9). Treating the cycloadduct 1.35 with 
BF3*Et2O readily cleaved the oxygen bridge and gave rise to aspidophytine 
precursor 1.36.
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Scheme 1.9 Padwa's total synthesis of Aspidophytine
Taking advantage of a facile oxonium ylide formation between a metal 
carbenoid and an ether, the Clark group developed an oxonium ylide formation/
[2,3]-sigmatropic rearrangement reaction cascade to access a group of oxygen- 
bridged macrocycles. One excellent example is shown in Scheme 1.10.17 
Starting from acid 1.40, diazo ketone 1.41 was obtained by first forming a mixed 
anhydride then reacting it with diazomethane. Diazo decomposition with 
Rh2(O2CCPh3)4 gave the alkene 1.42 via the dipolar cycloaddition of 1.44. Furan
1.42 was advanced to the natural product (-) Cladiell-11-ene-3,6,7-triol.
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Scheme 1.10 Clark's synthesis o f (-) Cladiell-11-ene-3,6,7-triol
X-H insertions occur when metal carbenoids interact with heteroatom- 
hydrogen bonds.18 It has been identified to be the preferred reaction pathway of 
metal carbenoids. Mechanistically, X-H insertion is probably distinct from C-H 
insertion as an ylide 1.48 probably is formed first, and then undergoes a [1,2] 
proton transfer to realize the insertion product (Scheme 1.11).
Notably, the Moody group has shown that amides could readily insert into the 
metal carbenoid derived from diazo ketoester 1.51 to provide compound 1.52, 
which then cyclized upon oxidation condition using PPh3/I2 to form oxazole 1.53 
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Scheme 1.12 Moody's total synthesis of siphonazole
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It has been long recognized that metal carbenoids react with alkenes to 
provide cyclopropanes.20 Both a concerted and a stepwise mechanism have 
been proposed (Scheme 1.13). The Davies group discovered that when an 
appropriate substrate was utilized, a subsequent Cope rearrangement could take 
place to form the cycloheptadiene. An elegant example came during their total 
synthesis of tremulenolide A (Scheme 1.14).21 Diazo 1.60 reacted with the less 
sterically hindered Z-alkene in 1.61 in a stereoselective manner to give 1.64 first. 
A subsequent Cope rearrangement provided cycloheptadiene 1.62 as a single 
diastereomer. Hydrogenation and lactone formation led to tremulenolide A.
The Davies group first demonstrated that donor-acceptor metal carbenoids 
participated in intermolecular C-H insertions with high efficiency and selectivity.22 
The optimal catalysts usually were proline-based rhodium carboxylates such as 
Rh2(DOSP)4. Mechanistically, C-H insertion with Rh carbenoids is believed to 
occur in a concerted manner. The hydrogen approaches the carbenoid center 
causing partial positive charge build-up on the carbon of the C-H bond as 
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Scheme 1.14 Davies' total synthesis of tremulenolide A
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Scheme 1.15 Mechanism of intermolecular C-H insertion
Due to their lower reactivity, when compared to traditional acceptor-acceptor 
type metal carbenoids, donor-acceptor metal carbenoids overcome the 
dimerization problem and are more selective towards insertions of different C-H 
bonds. For example, simple alkanes have been shown to participate in 
intermolecular C-H insertions with good chemo-, regio- and enantioselectivity 
(Scheme 1.16).23 In general, secondary C-H bonds are the most reactive 
towards C-H insertions.23 Cyclopentane 1.70 and cyclohexane 1.72 were very 
good substrates for C-H insertions as reactions completed at low temperatures.24
13
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Scheme 1.16 C-H insertion of simple alkanes
In contrast, the C-H insertion of 2,2-dimethylbutane 1.74 took place preferably at 
the primary C-H bond and elevated temperatures had to be applied. Presumably, 
it is because of the steric bulkiness surrounding the secondary C-H bond.24
Allylic and benzylic C-H bonds are good substrates for intermolecular C-H 
insertions as the partial positive charge generated on the allylic or benzylic 
carbon can be efficiently stabilized by conjugation (Scheme 1.17).25 Allyl silyl 
ethers such as 1.81 are even better substrates due to the additional stabilizing 
effect of the electron-rich siloxy group.24 Compound 1.82 was isolated in 
excellent diastereoselectivity and good enantioselectivity when reacting 1.69 with 
1.81 in the presence of Rh2(DOSP)4.
14
Ph C O * .  p Y  Rh2(S' ° T 7)64(1 j p ^ Y C02Me
N2 2,2-dimethylbutane, 23 °C  M e O " * * ^ ^  ^
1.69 1.77 (67%, 79% ee) 1 7 8
P h ^ C O z M e  Rh2(S-DOSP)4 (1 mol%)
N* 2,2-dimethylbutane, 23 °C  M e O '" ^ '^  C 0 2Me
1.69 1.79 1.80
(67%, 79% ee)
Ph ^  ^CO,Me 1.76 _
n + TBS ° v^ ^ s ^ \   -------►  Me02CN N  havane 93 °C.
^gg 1 8 1  (40%, 78% ee, >95:5 dr)
Rh2(S-DOSP)4 (1 mol%) 
1.76________
hexane, 23 °C
Scheme 1.17 C-H insertions into benzylic and allylic C-H bonds
Another type of C-H bond that is susceptible to the C-H insertion reaction is 
the C-H bond a to a heteroatom. Acyclic substrates such as amines and ethers 
reacted with aryl diazo esters in the presence of Rh2(DOSP)4 to provide C-H 
insertion products 1.85 and 1.87 with good diastereo- and enantiocontrol 
(Scheme 1.18).24’ 25b’ 26 Interestingly, while insertion of the donor-acceptor metal 
carbenoid into Boc- protected pyrrolidine 1.91 proceeded with high 
diastereoselectivity, C-H insertion into the corresponding furan 1.88 only gave 
quite low diastereoselectivity.24, 27
A general reactivity trend has been established in order to understand the 
selectivity of intermolecular insertion into different C-H bonds (Scheme 1.19). 
The C-H insertion of 1,4-cyclohexadiene 1.93 was determined to be the fastest, 
followed by that of the C-H bond adjacent to a heteroatom. The reaction of 
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Scheme 1.19 Relative rates for C-H insertion of metal carbenoids
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In the total synthesis of (+)-imperanene, the key step was an intermolecular 
C-H insertion of vinyl diazo acetate 1.96 with benzylic methyl group in substrate 
1.97 (Scheme 1.20).28 In the presence of Rh2(R-DOSP)4 this transformation 
produced the desired product 1.98 with 43% yield and 91% ee. Further functional 
group manipulations generated the natural product.
1.3 Vinyl metal carbenoids: versatile synthetic intermediates 
The vinyl metal carbenoid is a more versatile synthetic intermediate than the 
simple metal carbenoid because further transformations can be easily carried out 
on the vinyl group. In addition, vinyl metal carbenoids show unique vinylogous 
reactivity. It is well known that vinyl metal carbenoids undergo cyclopropanation 
and subsequent rearrangements resulting in formal [3+2] cycloadditions. As 
illustrated in Scheme 1.21, a stereoselective cyclopropanation between vinyl 
diazo ester 1.100 and vinyl ether 1.101 in the presence of Rh2(DOSP)4 gave 
cyclopropane 1.102.29 Treating 1.102 with Et2AlCl rendered the cyclopentene 
1.103 with some loss of optical purity. Interestingly, the optical purity was mostly 
retained when a more sophisticated substrate such as 1.105 was converted into 
1.106. On the other hand, [3+4] cycloaddition is highly stereoselective because 
both the cyclopropanation and subsequent Cope rearrangement take place in 
excellent stereocontrol (Scheme 1.22).30 Notably, Cope rearrangement is 
believed to accomplish through a boat-like transition state as indicated in 1.110. 
It’s worth mentioning that cyclopropanation of diene 1.107 only happened on the 
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Scheme 1.22 [3+4] Annulation of vinyl carbenoids and vinyl ethers
A very interesting reaction of vinyl metal carbenoids is the allylic C-H 
insertion-Cope rearrangement. The Davies group has extensively studied this 
reaction in an effort to expand the substrate scope and to illustrate the 
mechanism of this reaction. In the total synthesis of elisapterosin B, the Davies 
group have demonstrated that diazo ester 1.114 reacted with compound 1.113 
enantio- and diastereoselectively. They believe a concerted allylic C-H 
activation/cope rearrangement mechanism is involved as illustrated by 1.117 
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Scheme 1.23 Davies's total synthesis of (-)-elisapterosin B
manipulations and then served as an advanced intermediate towards the total 
synthesis of elisapterosin B.
The Nikolaev group reported that when E-vinyl diazo ester 1.118 was treated 
with Rh2(Oct)4, furan 1.119 was formed in 64% yield (Scheme 1.24).32 
Presumably, this reaction was completed through a cyclic oxonium ylide 1.120. 










Scheme 1.24 Synthesis o f furans from E-vinyl diazo ester
1.4 Conclusion
Metal carbenoid chemistry has become a powerful tool for natural product 
synthesis. Its unique reactivity profile receives more and more attention from the 
synthetic community including our group. In the next three chapters, our efforts in 
utilizing diazo phosphonates as useful synthetic intermediates will be illustrated.
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CHAPTER 2
VINYL DIAZO PHOSPHONATES AS PRECURSORS FOR 
INDOLINES AND CYCLOPENTENES
2.1 Vinyl diazo phosphonates as precursors for indolines
2.1.1 Introduction
Indole natural products receive a significant amount of attention due to their 
prominent anti-bacterial, antifungal and anticancer activities.1 Our group has 
been engaged in utilizing thioindoles as precursors for complex indole synthesis.
Notably, former group member Dr. Kennedy discovered that when treating 2- 
thioindole 2.1 with diazo ester 2.2, a sulfur ylide 2.4 was formed first, which 
subsequently underwent a [1,2]-Stevens rearrangement to give insertion product
2.3 in 94% yield (Scheme 2.1).2 In contrast, when vinyl diazo ester 2.5 was 
subjected to 2.1 under the same condition, a [3,3]-sigmatropic rearrangement 
occurred giving rise to C-3 quaternary-substituted indoline 2.6 (Scheme 2.2).
Former group member Dr. Novikov conducted an extensive study on this 
interesting rearrangement and demonstrated that the substrate scope was quite 
broad as shown in Table 2.1.3 However, diastereoselectivities were quite low in 
all cases. The relative stereochemistry of the major isomer of 2.20 was assigned 
by X-ray crystallography (Scheme 2.3).
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Scheme 2.2 [3,3] rearrangement of thioindoles and vinyl diazo esters
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Table 2.1 [3,3]-Sigmatropic rearrangement: substrate scope
R i n 2
Mr2'  —  C02Et 
2.8-2.13
2.1
Rh2(OAc)4(5 mol %) 








entry diazo Ri R2 product d.r. yield
1 2.8 H Me 2.14 2:1 93%
2 2.9 H CO2Et 2.15 2:1 82%
3 2.10 H Ph 2.16 1:1 95%
4 2.11 Cl H 2.17 3:1 98%
5 2.12 Me Me 2.18 n.a. 86%
6 2.13 Me Ph 2.19 3:2 96%
Me02C ^ /C° 2Me
Y H- . f
2.20N ) ~
Scheme 2.3 structure of major isomer 1.94 determined by X-ray
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Former group member Dr. Boyarskikh investigated the effect of the 
substitutions on the thioindole for the [3,3]-sigmatropic rearrangement.4 While he 
found the electronic environment of the arene groups had little effect on 
diastereoselectivity, enhancement was achieved when increasing the bulkiness 
of the arene group (Table 2.2). He also tested chiral rhodium catalysts for this 
transformation. Only moderate enantioselectivities were achieved.5
Table 2.2 Diastereoselectivity o f [3,3]-sigmatropic rearrangement
" V Y








entry Ar d.r. (major/minor) yield
1 Ph 7:1 82%
2 4-OMeC6H4 7:1 86%
3 4 -NO2C6H4 7:1 74%
4 2-FC6H4 7:1 74%
5 2-MeC6H4 11:1 75%
6 2,6-dimethylphenyl 15:1 96%
7 2-/PrC6H4 18:1 91%
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In order to further expand the substrate scope of this rearrangement, Dr. 
Boyarskikh investigated vinylogous diazo systems other than diazo esters.5 He 
turned his attention to diazo phosphonates due to the fact that phosphonates 
play an important role both in synthetic chemistry and biological systems. Two 
donor-acceptor type vinyl diazo phosphonates 2.42 and 2.43 were synthesized 
based on a known procedure which was then optimized by Dr. Boyarskikh 
(Scheme 2.4). The synthesis of acceptor-acceptor type vinyl diazo phosphonate 
2.49 was also successful (Scheme 2.5).
When treated with 2-thioindole 2.50, the reaction of diazo phosphonate 2.42,
2.43 and 2.49 gave the desired C-3 quaternary substituted indolines in good yield 
(Scheme 2.6).5 Interestingly, the acceptor-acceptor type diazo phosphonate 2.49 
showed a higher diastereoselectivity compared to the other donor-acceptor type 
diazo phosphonate 2.42. Essentially, one single diastereomer of 2.53 was 
formed when 2.49 was treated with 2.50.
R R R O
oxalyl chloride 
CH2CI2, 0 °C
2.35, R = Me
2.36, R = H
2.37, R = Me, 71%
O
2.38, R= H, 15%
2.38, R= Me, 41%
NH2NHTs, TsOH 
---- -------- :--------- ►
benzene, reflux ii
O O
2.40, R = H
2.41, R = Me
2.42, R = H, 34% over two steps
2.43, R = Me, 63% over two steps
Scheme 2.4 Synthesis of donor-acceptor vinyl diazo phosphonates
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Scheme 2.6 [3,3]-Sigmatropic rearrangement of vinyl diazo phosphonates
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2.1.2 Synthesis of indolines via a [3,3]-sigmatropic rearrangement
Although Dr. Boyarskikh was able to obtain several vinyl diazo phosphonates 
and successfully coupled them with 2-thioindoles, the lengthy and low-yielding 
procedure for synthesizing the diazo precursors greatly reduced their synthetic 
utility.
Preliminary data suggested that acceptor-acceptor type vinyl diazo 
phosphonate provided better diastereoselectivity when treated with 2-thioindoles 
in the presence of a rhodium catalyst. Encouraged by this result, we started to 
consider whether there was a better way to access the acceptor-acceptor type 
diazo phosphonates. It had been reported that phosphonocrotonate 2.56 could 
be made via an Arbuzov reaction by simply treating methyl bromocrotonate 2.54 
with triethyl phosphite 2.55 (Scheme 2.7). Unfortunately, when treating 
compound 2.56 with ABSA and DBU, we were unable to isolate the desired diazo 
product.
In 2002, the Marko group reported that a stereoselective monoalkylation of 
phosphonocrotonate 2.56 could be achieved by treating it with a base such as 
LiHMDS and an alkylating reagent (Scheme 2.8).6 The alkylation happened 
solely at the position adjacent to the ester group. Only the E-isomer of the 
phosphonocrotonate product 2.57 was formed. Due to the fact that phosphonate 
2.47 formed diazo phosphonate 2.49 successfully by a standard diazo transfer 
protocol, we believed that the alkylation would allow us to access a series of 
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Scheme 2.7 Synthesis of phosphonocrotonate and its diazo formation
Gratifyingly, following the above-mentioned method, methyl substituted 
phosphonocrotonate 2.47 was synthesized in good yield (Scheme 2.9). Further 
structure elucidation proved that it was identical with the compound Dr. 
Boyarskikh had made using the previous method. Treating the substituted 
phosphonocrotonate with the standard diazo transfer condition using ABSA and 
DBU provided the desired diazo phosphonate 2.49 in 60% yield. When treated 
with thioindole, the desired C-3 quaternary indoline 2.53 was formed as a single 
diastereomer.
We were very excited about this result because it could provide a 
straightforward pathway towards the synthesis of indolines bearing a 
phosphonate group. So we decided to further explore the substrate scope of this 
transformation. Alkylation with iodoethane went smoothly to provide compound 
2.58 although the yield was lower (Scheme 2.10). Diazo phosphonate 2.59 was 
formed following the previously described procedure. To our surprise, when 
treating the diazo 2.59 with 2-thioindole, a new product was formed in addition to 
the expected indoline product 2.60. Careful NMR analysis revealed that the new 
compound was actually cyclopentene 2.61.7 Presumably, the cyclopentene 2.61 



















Me02C ^ ^ ^ P ' OEt
y '  OEt ------------------------------ ;
!^e CH3CN, 0 °C  to rt
ABSA, DBU
2.47 (60%)
” e0!Cy V c° ° * ‘
Me Nz
2.49 CH2CI2, rt 2.53, 83%, >95:5 dr
Scheme 2.9 [3,3]-Sigmatropic rearrangement of vinyl diazo phosphonate
Me02Cs
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2.61, 55%
Scheme 2.10 Unexpected cyclopentene formation
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2.1.3 Efforts towards the total synthesis of PF1270 
Natural products bearing an oxoindole scaffold are widely prevalent in nature. 
We decided to target oxoindole natural products because they can be easily 
prepared from our C-3 quaternary substituted indolines. One family of natural 
products we were particularly interested in were PF1270 A, B and C, which were 
isolated in 2007 from culture broth of fungal strain PF1270 (Scheme 2.11).8 In 
preliminary studies they displayed high affinity towards the rat histamine H3 
receptors (Ki 0.058, 0.17 and 0.19 mM, respectively) and human Histamine H3 
receptors (Ki 0.047, 0.12 and 0.22 mM, respectively).
Retrosynthetically, PF 1270 can be synthesized from amide 2.65, which is 
derived from phosphonate 2.66 via a Horner-Emmons reaction and functional 
group manipulation (Scheme 2.12). The cyclopentane ring in 2.66 would be 
formed by an intramolecular Michael addition of the a-carbon of the ester group 
to the vinyl phosphonate in compound 2.67.
Preliminary results towards the intramolecular Michael addition were 
encouraging. Dr. Boyarskikh had demonstrated that a related cyclization was 
viable by treating a,p-unsaturated ester 2.68 with f-BuOK (Scheme 2.13).5 
However, attempts to facilitate the cyclization of vinyl phosphonate 2.70 to 
directly form 2.71 was unsuccessful (Scheme 2.14). Instead, Dr. Boyaskikh 
discovered that a cyclic phosphonate 2.72 was formed when treating 2.52 with 
LDA and TMSCl. Corresponding alcohol 2.73 could be formed by acidic 
hydrolysis. However, we were not able to convert either 2.72 or 2.73 to the 




2.62, PF1270A, R = n-Pr
2.63, PF1270B, R = Et
2.64, PF1270C, R = Me








Scheme 2.12 Retrosynthetic Analysis of PF1270
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KOf-Bu, THF, rt, 
dr = 7:1 
(75%)





2.70, R = H or C 02Me
Me02C
2.71, R = H or C 02Me
Me02C Me “ e
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Me02C Me Y e
2.73
Scheme 2.14 Unsuccessful Michael addition of vinyl phosphonates
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2.2 Vinyl diazo phosphonates as precursors for cyclopentenes
2.2.1 Introduction
Although intramolecular C-H insertions of diazo carbonyl compounds to form 
cyclopentanes are well known, reports of its diazo phosphonate counterpart have 
been rare and limited to a-diazo p-ketophosphonates. A good example was 
reported by Corbel et al as a series of a-diazo p-ketophosphonates or a-diazo p- 
ketophosphine oxides were treated with rhodium acetate and rendered the 
formation of phosphoryl cyclopentanones in moderate yield (Scheme 2.15).9 To 
the best of our knowledge intramolecular C-H insertion of vinyl diazo 
phosphonates or esters has not yet been reported.
O r  w
R ' Y ^ V  ^ 3  Rh2(OAc)4, CH2CI2>
r 2 n 2 ^  W - R 2 R3
2.74 Ri
2.75 - 2.80R-), R2 = alkyl; 
R3 = OEt or Ph
2.75, 67% 2.77, 48% 2.78, 70%
2.79, 50% 2.80, 33%
Scheme 2.15 Intramolecular C-H insertion of diazo ketophosphonates
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We came to believe that the synthetically unique transformations of vinyl 
diazo phosphonates mentioned above can be useful for the construction of bio­
active molecules. Of particular interest were the newly formed cyclopentenyl 
phosphonates which resemble carbocyclic nucleosides.10 Carbocyclic 
nucleosides are nucleoside analogues that have attracted interest from medicinal 
chemists due to their applications as anti-viral, anti-HIV and anticancer agents.10 
Their structural similarities to nucleosides provide the hope that they are likely to 
bind to the same protein targets, while the lack of a glycosidic linkage increases 
their stability against enzymatic degradation. Cyclopentane type carbocyclic 
nucleosides are found both in nature and synthesized artificially. A few 
interesting carbocyclic nucleosides are shown in Scheme 2.16. Neplanocin A is a 
naturally occurring carbocyclic nucleoside that has shown significant antitumor 
activity against L1102 Leukemia in mice.11 (-)-Carbovir was discovered as early 
as 1989 and demonstrated anti-HIV activity.12 (-)-Abacavir exhibited even 
stronger anti-HIV activity and is the major effective component in the FDA 
approved drug Ziagen.13
2.2.2 Synthesis of cyclopentenes via an intramolecular C-H insertion 
Interested in the potential synthetic utility of cyclopentenyl phosphonates, we 
decided to expand the substrate scope of this methodology. Alkylation with 
primary iodides or triflates provided the desired mono-substituted phosphonates 
(Scheme 2.17). The relatively low yields for some iodides were mainly due to 
dialkylation and decomposition of the phosphonocrotonate precursor 2.56.
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Base >( Base 0  ^  *”1$  "°ipi J t f -
OHOH OHOH r
Normal nucleosides Carbocyclic nucleosides Cyclopentenyl phosphonates 
2.81 2.82 2.83
n h 2 ^ n h  o h
<'xX <'li*1
N M° Y y  H o - y Y  N NH2
\  i  \  \ = J
HO OH HO OH
2.84 2.85 2.86
Neplanocin A (-)-abacavir (-)-carbovir
Scheme 2.16 Structure o f carbocyclic nucleosides
Triflates should be the preferred alkylating reagents because first, triflates 
normally gave higher yield than the corresponding iodides; second, simple 
alcohol precursors for making triflates are commercially available. It is also 
noteworthy to mention that in both Marko and our experiments, alkylations 
occurred in a regio- and stereocontrolled manner as the alkylations happened 
solely on the a-carbon of the ester and the resulting a,p-unsaturated esters were 
isolated exclusively as the E alkenes.
Diazo transfer of the substituted phosphonates went uneventfully to provide 
the corresponding diazo phosphonates in good yield (Scheme 2.18). The 
configurations of the alkenes were determined to be E-isomers Based on NOE 
experiments.
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Scheme 2.18 Formation of vinyl diazo phosphonates: substrate scope
With the diazo phosphonates in hand, intramolecular C-H insertions were 
performed in the presence of Rh2(OAc)4. To our delight, the desired 
cyclopentenes were the only isolated products in high yield (Scheme 2.19). 
Primary, secondary and tertiary C-H bonds were all suitable substrates for the C­
H insertion reactions. Diastereoselectivity of the secondary C-H insertion was 
generally moderate. However, the thermodynamically more stable trans- isomer 
could be obtained by treating the mixture of diastereomers with DBU in CH2Cl2
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m "  OEt
M e02C . . P ' 0 E t Rh2(OAc)4 (5 mmol%) M e02CN x S ^ P ' o t t
r  n OEt — CHCI — ► v J  0EtR N2 CH2CI2, rt '---- ^ . R,
R"
2.94 2.102
Me02C ^ s ^ P 'OEt
X j  0Et
2.61,67%
Me02C ^ s ^ P 'OEt
0Et
2.103, 89%, 5:1 dr
Me02C ^ ^ P ' OEt
2.104, 87%
2.105, 82%, 2:1 dr
M e O jC ^ ^ P '-O E t
OEt
Ph
2.106, 78%, 2:1 dr
MGO2C.
2.108, 95%, 5:1 dr 0TBS
M0O2C OEt
OTBS
2.107, 3:2 dr, 90%, 
complete chirality rentention
Scheme 2.19 C-H insertion of vinyl diazo phosphonate: substrate scope
for 1h (Scheme 2.20). When an optically pure diazo phosphonate 2.100 was 
used in the reaction, the cyclopentene was formed as a 3:2 mixture of two 
diastereomers. We were pleased to find out that the absolute stereochemistry of 
the diazo phosphonate was completely transferred to the product as shown by 
chiral HPLC. Based on Taber’s work, we believe that the absolute 
stereochemistry of the diazo 2.100 was retained in the reaction.14 These findings 
demonstrate that this methodology can serve as a useful tool for diastereo- and 






2.103, R = Me, 5:1 dr
2.105, R = vinyl, 2:1 dr
2.106, R = Ph, 2:1 dr
2.103, R = Me, >95:5 dr
2.105, R = vinyl, >95:5 dr
2.106, R = Ph, >95:5 dr
Scheme 2.20 Equilibration to trans phosphonates
Another rather unique substrate was diazo phosphonate 2.97 having an allyl 
group pendant to the diazo functionality. When treated with Rh2(OAc)4 2.97 
readily participated in the cyclopropanation reaction and gave the bicycle [3.1.0] 
substrates 2.109 and 2.110 (Table 2.3). Presumably, the minor product 2.110 
was formed either through a [3+2] cycloaddition or isomerization of compound 
2.109.
Asymmetric C-H insertion reactions have also been examined. Unfortunately, 
treating vinyl diazo phosphonates 2.99 with a number of chiral dirhodium 
catalysts including Rh2(R-DOSP)4, Rh2(R-BPTA)4, and Rh2(4S-MEAZ)4 resulted 
in minimal enantioselectivity, although the yield was comparable with achiral 
dirhodium catalyst such as Rh(OAc)2 (Scheme 2.21). Given the fact that the
[3,3]-sigmatropic rearrangement between 2-thioindole and vinyl diazo 
phosphonate also provided very low enantioselectivity when chiral dirhodium 
catalyst was applied, we believed that the chiral ligand on the dirhodium catalyst 
was too far-away from the diazo carbon resulting in unsatisfactory control of its 
stereochemistry.
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Table 2.3 Cyclopropanation of vinyl diazo phosphonate
2.97 2.109, major 2.110, minor
entry catalyst solvent temp. time yield major: minora
1 Rh2(OAc)4 CH2Cl2 rt 2d 79% 4:1
2 Rh2(OAc)4 benzene 80 oC 4h 80% 6:1
3 Rh2(OAc)4 toluene 110 oC 2h 80% 10:1
4 Rh2(O2CCF3)4 CH2Cl2 rt 12h 81% 5:1
5 none benzene 80oC 8h 64% > 95:5
6 BINOL CH2Cl2 rt 2d 55% > 95:5
7 Cu(CH3CN)4PF6 CH2Cl2 rt 10 min 93% >95:5
a Ratio of diastereomers determined by the integrations of the vinyl proton peak 
in the 1H NMR spectra of the crude reaction mixture.
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Scheme 2.21 Chiral catalyst for intramolecular C-H insertion
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2.2.3 Synthesis of spiro bicyclic carbocycles 
The high efficiency and specificity of cyclopentene ring formation suggest to 
us that this methodology can be applied to the construction of more complex 
structures. Since insertion into a tertiary C-H bond was successful, we 
envisioned that when cyclohexamethyl triflate was applied as the alkylating 
reagent, the subsequent reaction would provide a [5,6]-spiro ring system. Several 
natural products with a spiro-fused ring system are shown here (Scheme 2.22). 
Elisapterosin B exhibited strong inhibitory activity (79%) against M. tuberculosis 
H37Rv at a concentration of 12.5 ^g/mL.15 Conidiogenones B showed significant 
antibacterial activity against several methicillin-resistant bacteria species each 
with MIC value of 8 mg/ml.16 Biological and clinic studies have shown that 
ingenol is a potent activator towards PKC and exhibited antitumor activity. 
Furthermore, some of the ingenol derivatives have been used as FDA approved 
drugs for treating skin cancer.17
Following the previously described route, alkylation with triflate 2.117 
provided cyclohexane containing phosphonate 2.118 in 63% yield (Scheme 2.23). 
Diazo formation of 2.118 went smoothly to realize the desired diazo phosphonate 
2.119. Intramolecular C-H insertion reaction proved to be highly efficient, as the 
desired cyclized product 2.120 was formed in 95% yield. Thus we demonstrated 
that synthesis of the [5,6]-spiro ring system is possible.
We have also utilized this methodology for the construction of [5,7]-spiro ring 
system, as shown in Scheme 2.24. Starting from cycloheptamethyl triflate, similar 








Scheme 2.22 Natural products containing spiro ring systems
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Scheme 2.23 Synthesis of [5,6]-spiro ring system

















Scheme 2.24 Synthesis of [5,7]-spiro ring system
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2.2.4 Synthesis of fused bicyclic carbocycles
Taking advantage of the labile phosphonate group, one can imagine that 
cyclopentenyl phosphonates are prone to Horner-Emmons reactions. 
Encouraged by the intermolecular Horner-Emmons reaction of 2.61 which 
provided the desired diene in moderate yield and diastereoselectivity, we set out 
to test whether the intramolecular Horner-Emmons reaction would give us a 
fused ring system such as [5,5], [5,6] and [5,7]- fused ring systems. The 
synthesis of [5,6]-fused system was examined first (Scheme 2.25). The suitable 
aldehyde substrate 2.126 was synthesized with no event from cyclopentene 
2.108 by deprotecting the TBS group and oxidizing the resulting alcohol with 
Dess-Martin periodinane. The [5,6]-fused ring system 2.127 was successfully 
generated in 67% yield by treating the aldehyde with NaHMDS.
However, similar conditions to cyclize aldehyde 2.128 or 2.129 failed to 
provide corresponding [5,5] and [5,7]-fused ring systems (Scheme 2.26). Various 
conditions have been tested and only decomposition was observed.
o o












NaHMDS, THF, 0 °C
(67%)
2.127
Scheme 2.25 Synthesis of [5,6]-fused ring system
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Oii^OEt „  _ _
Me02C. .PC MeQ2C^ Me02C>_ x v ^ <.
2 r  OEt NaHMDS. THF > = \  2
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2.128, n = 2 2.130 2.131
2.129, n = 4
Scheme 2.26 Unsuccessful attempts towards [5,5] and [5,7]-fused systems
2.3 Conclusion
A series of vinyl diazo phosphonates were readily prepared from known 
phosphonocrotonate 2.56. Methyl substituted vinyl diazo phosphonate 2.49 
underwent a [3,3]-sigmatropic rearrangement to provide C-3 quaternary indoline 
2.53. In contrast, intramolecular C-H insertions took place to form cyclopentene 
phosphonates when treating diazo phosphonates 2.95 - 2.101 and 2.59 with 
Rh2(OAc)4. Both spiro and fused ring systems can be accessed using this 
methodology.
Future endeavors will include utilizing the intramolecular C-H insertion of 
diazo phosphonates in the synthesis of biological active small molecules. 
Carbocyclic nucleosides represent a type of promising targets for this 
methodology.
2.4 Experimental
NMR spectra were recorded on a Varian Inova-500, a Varian Unity-300, a 
Varian Inova-400 or a Varian VXR-500 spectrometer. Chemical shifts were 
reported in 5, parts per million (ppm), relative to chloroform (7.25), benzene 
(7.16), or dichloromethane (5.29) as internal standards. Coupling constants, J,
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were reported in Hertz (Hz) and refer to apparent peak multiplicities and not true 
coupling constants. Mass spectra were recorded at the Mass Spectrometry 
Facility at the Department of Chemistry of the University of Utah at Salt Lake City 
on a Finnigan MAT 95 mass spectrometer. IR spectra were recorded on a Bruker 
Tensor 27 FTIR spectrometer. Solvents were purified according to the guidelines 
in Purification of Common Laboratory Chemicals (Armarego. W. L. F. and Chai, 
C. L. L., Oxford, 2009). Spectroscopic grade CH3CN was stored over activated 
4A molecular sieves and used without additional purification. All other reagents 
were used without purification. Unless otherwise stated, all reactions were run 
under an atmosphere of dried nitrogen in flame-dried glassware. Concentration 
refers to removal of solvent under reduced pressure (house vacuum at ca. 20 
mmHg).
2.4.1 General procedure for the alkylation of phosphonocrotonate 
To a solution of phosphonocrotonate 2.56 (ca. 2.0 mmol) in 10 mL of THF at 
0 °C was added LiHMDS (ca. 2.0 mmol) dropwise. After stirring at 0 °C for 0.5 h, 
the solution was warmed to rt and a solution of alkyl iodide or triflate (ca. 1.0 
mmol) in 2 mL of THF was added dropwise. The resulting reaction mixture was 
stirred for 2 h and the reaction was quenched with sat. NH4Cl (aq., 10 mL). The 
organic layer was separated and the aqueous layer was extracted with ethyl 
acetate (3^10 mL). The organic layers were combined, dried (Na2SO4), and 




(E)-methyl 4-(diethoxyphosphoryl)-2-methylbut-2-enoate (2.47). Prepared 
according to the general procedure using phosphonocrotonate 2.56 (0.472 g,
2.00 mmol), THF (10 mL), LiHMDS (2.0 mL of a 1.0 M solution in THF, 2.0 mmol) 
and Mel (62.3 ^L, 1.00 mmol) in THF (2 mL) to give 0.188 g of 2.47 (75%) as a 
colorless oil after flash chromatography (1:2 hexanes:ethyl acetate).
2.47: 1H NMR (300 MHz, CDCls) 5 6.78 - 6.72 (m, 1H), 4.14 - 4.07 (m, 4H), 3.74 
(s, 3H), 2.73 (ddd, J = 22.6, 8.3, 0.8 Hz, 2H), 1.90 - 1.87 (m, 3H), 1.38 - 1.25 (m, 
6H); 13C NMR (75 MHz, CDCls) 5 168.0 (d, J = 3.5 Hz), 131.7 (d, J = 13.5 Hz),
130.7 (d, J = 11.0 Hz), 62.4 (d, J = 6.5 Hz), 52.2, 27.8 (d, J = 138.2 Hz), 16.7 (d, 
J = 6.0 Hz), 12.8 (d, J = 2.6 Hz); IR (neat) 2984, 1716, 1651, 1437, 1252, 1165, 
1049, 1024, 965 cm-1; LRMS m/z calcd for C10H19O5PNa 273.1 [M+Na]+, found
273.0
o
Me02Cv^ Ns^ | i ' OEt 
y ' OEt 
Et
2.58
(E)-methyl 4-(diethoxyphosphoryl)-2-ethylbut-2-enoate (2.58). Prepared 
according to the general procedure using phosphonocrotonate 2.56 (0.472 g,
2.00 mmol), THF (10 mL), LiHMDS (2.0 mL of a 1.0 M solution in THF, 2.0 mmol) 
and Etl (80.7 ^L, 1.00 mmol) in THF (2 mL) to give 0.087 g of 2.58 (33%) as a 
colorless oil after flash chromatography (1:2 hexanes:ethyl acetate).
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2.58: 1H NMR (300 MHz, CDCb) 5 6.70 (dt, J = 7.6, 7.6 Hz, 1H), 4.16 - 4.05 (m, 
4H), 3.73 (s, 3H), 2.73 (dd, J = 23.4, 8.2 Hz, 2H), 2.33 (dq, J = 7.6, 2.2 Hz, 2H),
1.31 (t, J = 7.1 Hz, 3H), 1.30 (t, J = 7.1 Hz, 3H), 1.01 (t, J = 7.5 Hz, 3H); 13C NMR 
(125 MHz, CDCls) 5 167.7, 137.7 (d, J = 14.1 Hz), 130.2 (d, J = 10.6 Hz), 62.4 (d, 
J = 6.5 Hz), 52.1, 27.5 (d, J = 139.5 Hz), 20.4 (d, J = 2.0 Hz), 16.7 (d, J = 6.1 Hz),
13.7 (d, J = 3.5 Hz); IR (neat) 2978, 1714, 1646, 1437, 1392, 1294, 1245, 1192, 
1165, 1117, 1094, 1050, 1022, 963 cm-1; LRMS m/z calcd for CnH^OsPNa
287.1 [M+Na]+, found 287.1
(E)-methyl 2-(2-(diethoxyphosphoryl)ethylidene)pentanoate (2.87). Prepared 
according to the general procedure using phosphonocrotonate 2.56 (0.472 g,
2.00 mmol), THF (10 mL), LiHMDS (2.0 mL of a 1.0 M solution in THF, 2.0 mmol) 
and PrI (97.5 |jL, 1.00 mmol) in THF (2 mL) to give 0.0974 g of 2.87 (35%) as a 
colorless oil after flash chromatography (1:2 hexanes:ethyl acetate).
2.87: 1H NMR (300 MHz, CDCls) 5 6.67 (q, J = 7.8 Hz, 1H), 4.11 - 3.98 (m, 4H),
3.67 (s, 3H), 2.67 (dd, J = 23.1, 8.1 Hz, 2H), 2.27 - 2.19 (m, 2H), 1.37 (qt, J = 7.5,
1.8 Hz, 2H), 1.25 (t, J = 7.1 Hz, 6H), 0.85 (t, J = 7.0 Hz, 3H); 13C NMR (75 MHz, 
CDCb) 5 167.8 (d, J = 3.0 Hz), 136.2 (d, J = 14.0 Hz), 130.7 (d, J = 11.0 Hz),
62.4 (d, J = 7.0 Hz), 52.0, 28.9 (d, J = 2.0 Hz), 27.6 (d, J = 138.7 Hz), 22.4 (d, J =
3.5 Hz), 16.6 (d, J = 6.0 Hz), 14.2; IR (neat) 2961, 1712, 1284, 1251, 1222, 1164, 










Prepared according to the general procedure using phosphonocrotonate 2.56 
(0.472 g, 2.00 mmol), THF (10 mL), LiHMDS (2.0 mL of a 1.0 M solution in THF,
2.0 mmol) and /-BuI (0.115 mL, 1.00 mmol) in THF (2 mL) to give 58.3 mg of 2.88 
(20%) as a colorless oil after flash chromatography (1:2 hexanes:ethyl acetate). 
2.88: 1H NMR (300 MHz, CDCls) 5 6.73 (q, J = 7.8 Hz, 1H), 4.11 - 3.89 (m, 4H),
3.67 (s, 3H), 2.68 (dd, J = 23.1, 8.1 Hz, 2H), 2.16 (dd, J = 7.2, 2.1 Hz, 2H), 1.70 
(sep, J = 6.7 Hz, 1H), 1.25 (t, J = 6.9 Hz, 6H), 0.81 (d, J = 6.7 Hz, 6H); 13C NMR 
(75 MHz, CDCls) 5 168.1, 135.6 (d, J = 14.5 Hz), 131.3 (d, J = 10.1 Hz), 62.4 (d, 
J = 6.5 Hz), 52.1, 35.7 (d, J = 2.0 Hz), 28.4 (d, J = 2.6 Hz), 27.9 (d, J = 138.8 Hz),
22.6, 16.6 (d, J = 6.0 Hz); IR (neat) 2956, 1714, 1289, 1252, 1227, 1163, 1096, 
1052, 1021, 961 cm-1; LRMS m/z calcd for C ^sO sP N a  315.1 [M+Na]+, found
315.1
(E)-methyl 2-(2-(diethoxyphosphoryl)ethylidene)pent-4-enoate (2.89).
Prepared according to the general procedure using phosphonocrotonate 2.56 
(0.709 g, 2.99 mmol), THF (15 mL), LiHMDS (3.15 mL of a 1.0 M solution in THF,




of 2.89 (51%) as a colorless oil after flash chromatography (1:2 hexanes:ethyl 
acetate).
2.89: 1H NMR (300 MHz, CDCl3) 5 6.84 (dt, J = 8.1, 8.1 Hz, 1H), 5.79 (ddt, J =
17.0, 10.2, 6.0 Hz, 1H), 5.04 (ddt, J = 9.1, 1.8, 1.8 Hz, 1H), 4.99 (dd, J = 1.8, 1.8 
Hz, 1H), 4.16 - 4.06 (m, 4H), 3.74 (s, 3H), 3.13 - 3.10 (m, 2H), 2.74 (dd, J = 23.2,
8.2 Hz, 2H), 1.32 (t, J = 7.0 Hz, 3H), 1.32 (t, J = 7.0 Hz, 3H); 13C NMR (75 MHz, 
CDCta) 5 167.4, 134.7 (d, J = 3.5 Hz), 133.6 (d, J = 14.1 Hz), 132.3 (d, J = 11.1 
Hz), 115.9, 62.4 (d, J = 6.6 Hz), 52.2, 30.9 (d, J = 2.0 Hz), 27.6 (d, J = 139.5 Hz),
16.7 (d, J = 6.0 Hz); IR (neat) 2982, 1715, 1639, 1438, 1252, 1214, 1023, 963 
cm-1; LRMS m/z calcd for C12H21OsPNa 299.1 [M+Na]+, found 299.1
(E)-methyl 2-(2-(diethoxyphosphoryl)ethylidene)hex-5-enoate (2.90).
Prepared according to the general procedure using phosphonocrotonate 2.56 
(0.472 g, 2.00 mmol), THF (10 mL), LiHMDS (2.0 mL of a 1.0 M solution in THF,
2.0 mmol) and homoallyl triflate (0.124 mg, 0.600 mmol) in THF (2 mL) to give
75.8 mg of 2.90 (44%) as a colorless oil after flash chromatography (1:2 
hexane/ethyl acetate).
2.90: 1H NMR (300 MHz, CDCl3) 5 6.73 (q, J = 8.1 Hz, 1H), 5.76 (ddt, J = 17.0,
10.3, 6.7 Hz, 1H), 5.03 - 4.88 (m, 2H), 4.15 - 4.00 (m, 4H), 3.70 (s, 3H), 2.70 (dd, 
J = 23.3, 8.2 Hz, 2H), 2.38 (td, J = 7.9, 1.6 Hz, 2H), 2.12 (dt, J = 7.2, 7.2 Hz, 2H), 
1.28 (t, J = 7.1 Hz, 6H); 13C NMR (75 MHz, CDCb) 5 167.6, 137.8, 135.5 (d, J =




Hz), 27.7 (d, J = 139.5 Hz), 26.5 (d, J = 2.0 Hz), 16.6 (d, J = 6.1 Hz); IR (neat)
2981, 1713, 1642, 1249, 1163, 1020, 962 cm-1; LRMS m/z calcd for 
C13H23O5PNa 313.1[M+Na]+, found 313.1
(E)-methyl 4-(diethoxyphosphoryl)-2-phenethylbut-2-enoate (2.91). Prepared 
according to the general procedure using phosphonocrotonate 2.56 (0.472 g,
2.00 mmol), THF (10 mL), LiHMDS (2.0 mL of a 1.0 M solution in THF, 2.0 mmol) 
and PhCH2CH2OTf (0.300 g, 1.20 mmol) in THF (2 mL) to give 0.191 g of 2.91 
(50%) as a colorless oil after flash chromatography (1:2 hexanes:ethyl acetate). 
2.91: 1H NMR (500 MHz, CDCb) 5 7.29 - 7.25 (m, 2H), 7.19 - 7.16 (m, 3H), 6.76 
(q, J = 8.1 Hz, 1H), 4.12 - 4.03 (m, 4H), 3.75 (s, 3H), 2.74 - 2.69 (m, 2H), 2.64 - 
2.58 (m, 2H), 2.48 (dd, J = 23.1, 8.0 Hz, 2H), 1.30 (t, J = 7.3 Hz, 6H); 13C NMR 
(125 MHz, CDCl3) 5 167.6, 141.6, 135.1 (d, J = 13.8 Hz), 131.8 (d, J = 10.6 Hz),
128.8 (d, J = 6.8 Hz), 128.7 (d, J = 9.8 Hz), 126.3, 62.4 (d, J = 8.3 Hz), 52.1, 35.2 
(d, J = 3.0 Hz), 29.3 (d, J = 2.4 Hz), 27.3 (d, J = 138.1 Hz), 16.6 (d, J = 6.1 Hz); 
IR (neat) 2981, 1712, 1437, 1248, 1195, 1174, 1095, 1019, 958 cm-1; LRMS m/z 








(diethoxyphosphoryl)ethylidene)-4- methylpentanoate (2.92). Prepared 
according to the general procedure using phosphonocrotonate 2.56 (59.3 mg,
2.00 mmol), THF (10 mL), LiHMDS (0.25 mL of a 1.0 M solution in THF, 0.25 
mmol) and (R)-3-(tert-butyldimethylsilyloxy)-2-methylpropyl triflate (42.2 mg, 
0.125 mmol) in THF (2 mL) to give 27.1 mg of 2.92 (51%) as a colorless oil after 
flash chromatography (1:2 hexane/ethyl acetate).
2.92: 1H NMR (300 MHz, CDCb) 5 6.80 (q, J = 8.1 Hz, 1H), 4.14 - 4.03 (m, 4H),
3.71 (s, 3H), 3.40 (d, J = 5.4 Hz, 2H), 2.83 (ddd, J = 15.1, 15.1, 8.3 Hz, 1 H), 2.71 
(ddd, J = 15.3m 15.3, 8.1 Hz, 1 H), 2.48 (ddd, J = 13.8, 6.4, 2.3 Hz, 1H), 2.14 
(ddd, J = 13.6, 8.0, 2.0 Hz, 1H), 1.84 - 1.67 (m, 1H), 1.29 (t, J = 7.2 Hz, 6H), 
0.875 (s, 9H), 0.83 (d, J = 6.9 Hz, 3H), 0.02 (s, 6H); 13C NMR (75 MHz, CDCb) 5
168.0, 135.2 (d, J = 14.0 Hz), 131.8 (d, J = 10.0 Hz), 67.5, 62.4 (d, J = 3.0 Hz),
62.3 (d, J = 2.6 Hz) , 52.1, 35.9 (d, J = 3.0 Hz), 30.1 (d, J = 2.6 Hz), 27.7 (d, J =
138.6 Hz), 26.1, 18.5, 16.8, 16.6 (d, J = 6.5 Hz), -5.2, -5.2; IR (neat) 2954, 2930, 
2857, 1717, 1253, 1218, 1165, 1086, 1026, 964 cm-1; LRMS m/z calcd for 
C19H39O6PSiNa 445.2 [M+Na]+, found 445.1
ethylidene) octanoate (2.93). Prepared according to the general procedure 
using phosphonocrotonate 2.56 (0.218 g, 0.920 mmol), THF (5 mL), LiHMDS 





butyldimethylsilyloxy)pentyl trifluoromethanesulfonate (0.162g, 0.460 mmol) in 
THF (2 mL) to give 87.0 mg of 2.93 (51%) as a colorless oil after flash 
chromatography (1 : 1  hexanes:ethyl acetate).
2.93: 1H NMR (300 MHz, CDCls) 5 6.72 (q, J = 7.8 Hz, 1H), 4.16 - 4.05 (m, 4H),
3.73 (s, 3H), 3.58 (t, J = 6.5 Hz, 2H), 2.72 (dd, J = 23.2, 8.2 Hz, 2H), 2.34 - 2.27 
(m, 2H), 1.54 - 1.44 (m, 2H), 1.44 - 1.28 (m, 12H), 0.87 (s, 9H), 0.03 (s, 6 H); 13C 
NMR (125 MHz, CDCls) 5 167.8 (d, J = 3.2 Hz), 136.5 (d, J = 14.4 Hz), 130.6 (d, 
J = 10.7 Hz), 63.4, 62.4 (d, J = 7.0 Hz), 52.0, 33.0, 29.7, 29.3 (d, J = 3.2 Hz),
27.6 (d, J = 143.1 Hz), 27.1 (d, J = 1.1 Hz), 26.2, 25.9, 16.6 (d, J = 5.9 Hz), -5.1; 
IR (neat) 2930, 2857, 2360, 2341, 1717, 1652, 1254, 1097, 1054, 1026, 963, 836, 
775 cm-1; LRMS m/z calcd for C21H43O6PSiNa 473.2 [M+Na]+, found 473.2
To a solution of phosphonate (ca. 0.10 mmol) and ABSA in 5 mL CH3CN at 
0 °C was added DBU dropwise. The resulting reaction mixture was warmed to rt 
and stirred for 12 h. Following concentration, the resulting residue was taken up 
in CH2Cl2 (9 mL). Concentration and flash chromatography gave diazo 
compounds.
(E)-methyl 4-diazo-4-(diethoxyphosphoryl)-2-methylbut-2-enoate (2.49).
Prepared according to the general procedure using phosphonate 2.47 (0.200 g,





0.800 mmol), ABSA (0.211 g, 0. 880 mmol) and DBU (0.143 mL, 0. 960 mmol) to 
give 0.141 g of 2.49 (64%) as a clear orange oil after flash chromatography (2:1 
hexane/ethyl acetate).
2.49: 1H NMR (500 MHz, CDCl3) 5 6.61 (dq, J = 7.9, 1.2 Hz, 1H), 4.25 - 4.06 (m, 
4H), 3.73 (s, 3H), 1.96 (d, J = 1.1 Hz, 3H), 1.35 (dt, J = 7.2, 0.8 Hz, 6H); 13C 
NMR (125 MHz, CDCb) 5 167.8, 124.7 (d, J = 10.6 Hz), 122.4 (d, J = 9.9 Hz),
63.4 (d, J = 5.3 Hz), 52.2, 16.3 (d, J = 6.9 Hz), 12.5; IR (neat) 2985, 2078, 1705, 
1616, 1436, 1259, 1133, 1045, 1015, 973 cm-1; LRMS m/z calcd for 





Prepared according to the general procedure using phosphonate 2.58 (0.106 g, 
0.401 mmol), ABSA (0.106 g, 0.44 mmol) and DBU (72.2 ^L, 0.48 mmol) to give 
85 mg of 2.59 (73%) as a clear orange oil after flash chromatography (2:1 
hexane/ethyl acetate).
2.59: 1H NMR (300 MHz, CDCls) 5 6.56 (d, J = 8.1 Hz, 1H), 4.25 - 4.06 (m, 4H),
3.73 (s, 3H), 2.37 (q, J = 7.6 Hz, 2H), 1.36 (t, J = 7.0 Hz, 3H), 1.36 (t, J = 7.3 Hz, 
3H), 1.04 (t, J = 7.5 Hz, 3H); 13C NMR (125 MHz, CDCls) 5 167.6, 128.5 (d, J =
9.9 Hz), 124.1 (d, J = 11.4 Hz), 63.5 (d, J = 5.3 Hz), 52.1, 20.0, 16.4 (d, J = 6.9 
Hz), 14.9; IR (neat) 2981, 2078, 1706, 1610, 1436, 1277, 1237, 1134, 1045, 
1016, 973 cm-1; LRMS m/z calcd for CnH 1gN2O6PNa 313.1[M+Na]+, found 313.0.
56
O




Prepared according to the general procedure using phosphonate 2.87 (52.7 mg, 
0.190 mmol), ABSA (50.0 mg, 0.210 mmol) and DBU (34.0 ^L, 0.227 mmol) to 
give 44.6 mg of 2.95 (77%) as a clear orange oil after flash chromatography (2:1 
hexane/ethyl acetate).
2.95: 1H NMR (300 MHz, CDCls) 5 6.57 (d, J = 8.3 Hz, 1H), 4.25 - 4.06 (m, 4H),
3.72 (s, 3H), 2.34 - 2.29 (m, 2H), 1.49 - 1.35 (partially obscured m, 2H), 1.36 (t, J 
= 7.0 Hz, 3H), 1.36 (t, J = 7.1 Hz, 3H), 0.92 (t, J = 7.3 Hz, 3H); 13C NMR (125 
MHz, CDCta) 5 167.8, 127.2 (d, J = 10.6 Hz), 124.4 (d, J = 10.6 Hz), 63.5 (d, J =
5.3 Hz), 52.1, 28.5, 23.6, 16.4 (d, J = 6.1 Hz), 13.8; IR (neat) 2961, 2074, 1706, 
1607, 1436, 1268, 1218, 1190, 1137, 1046, 1017, 973 cm-1; LRMS m/z calcd for 
C12H21N2OsPNa 327.1 [M+Na]+, found 327.1.
(E)-methyl 4-diazo-4-(diethoxyphosphoryl)-2-methylbut-2-enoate (2.96).
Prepared according to the general procedure using phosphonate 2.88 (29.1 mg, 
0.100 mmol), ABSA (26.4 mg, 0.11 mmol) and DBU (18.0 ^L, 0.12 mmol) to give





2.96: 1H NMR (300 MHz, CDCl3) 5 6.62 (d, J = 8.3 Hz, 1H), 4.25 - 4.06 (m, 4H),
3.73 (s, 3H), 2.24 (d, J = 7.4 Hz, 2H), 1.71 (sep, J = 6.9 Hz, 1H), 1.36 (t, J = 7.2 
Hz, 3H), 1.35 (t, J = 7.2 Hz, 3H), 0.89 (d, J = 6.7 Hz, 6H); 13C NMR (125 MHz, 
CDCta) 5 168.1, 126.5 (d, J = 10.6 Hz), 124.7 (d, J = 11.4 Hz), 63.5 (d, J = 5.3 
Hz), 52.1, 34.6, 29.1, 22.1, 16.4 (d, J = 6.9 Hz); IR (neat) 2958, 2870, 2076, 1707, 
1605, 1270, 1221, 1139, 1046, 1017, 973 cm-1; LRMS m/z calcd for 
C13H23N2O5PNa 341.1 [M+Na]+, found 341.1.
(2.97). Prepared according to the general procedure using phosphonate 2.89 
(200 mg, 0.724 mmol), ABSA (191 mg, 0.796 mmol) and DBU (0.13 mL, 0.87 
mmol) to give 148 mg of 2.97 (67%) as a clear orange oil after flash 
chromatography (2:1 hexane/ethyl acetate).
2.97: 1H NMR (300 MHz, CDCb) 5 6.76 (d, J = 8.0 Hz, 1H), 5.92 - 5.79 (m, 1H)
5.09 - 4.96 (m, 2H), 4.25 - 4.08 (m, 4H), 3.74 (s, 3H), 3.16 - 3.13 (m, 2H), 1.36 (t, 
J = 7.1 Hz); 13C NMR (75 MHz, CDCb) 5 167.5,135.6, 126.5 (d, J = 11.1 Hz),
123.2 (d, J = 10.3 Hz), 115.7, 63.5 (d, J = 5.3 Hz), 52.3, 30.1, 16.4 (d, J = 6.9 Hz); 
IR (neat) 2983, 2078, 1706, 1608, 1437, 1267, 1204, 1016, 973 cm-1; LRMS m/z 








Prepared according to the general procedure using phosphonate 2.90 (38.0 mg, 
0.120 mmol), ABSA (34.6 mg, 0.144 mmol) and DBU (23.5 ^L, 0.160 mmol) to 
give 31.4 mg of 2.98 (76%) as a clear orange oil after flash chromatography (2:1 
hexane/ethyl acetate).
2.98: 1H NMR (300 MHz, CDCb) 5 6.62 (d, J = 8.2 Hz, 1H), 5.78 (ddt, J = 16.9,
10.0, 6.7 Hz, 1H), 5.04 (ddt, J = 17.0, 1.5, 1.5 Hz, 1H), 4.99 (ddt, J = 10.1, 1.8,
1.1 Hz, 1H), 4.26-4.06 (m, 4H), 3.74 (s, 3H), 2.47 - 2.42 (m, 2H), 2.21 - 2.11 (m, 
2H), 1.37 (t, J = 7.1 Hz, 3H), 1.36 (t, J = 7.2 Hz, 3H); 13C NMR (125 MHz, CDCb) 
5 167.6, 137.1, 126.1 (d, J = 10.6 Hz), 124.9 (d, J = 11.4 Hz), 115.9, 63.5 (d, J =
5.3 Hz), 52.2, 34.1, 26.1, 16.4 (d, J = 6.1 Hz); IR (neat) 2982, 2076, 1705, 1608, 
1436, 1260, 1198, 1137, 973 cm-1; LRMS m/z calcd for C ^ ^ O s P N a  339.1 
[M+Na]+, found 339.1.
(E)-methyl 4-diazo-4-(diethoxyphosphoryl)-2-methylbut-2-enoate (2.99).
Prepared according to the general procedure using phosphonate 2.91 (38.0 mg, 




give 35.2 mg of 2.99 (86%) as a clear orange oil after flash chromatography (2:1 
hexane/ethyl acetate).
2.99: 1H NMR (300 MHz, CDCb) 5 7.31 - 7.26 (m, 2H), 7.22 - 7.17 (m, 3H), 6.64 
(d, J = 8.4 Hz, 1H), 4.22 - 4.02 (m, 4H), 3.76 (s, 3H), 2.76 - 2.60 (m, 4H), 1.36 (t, 
J = 7.1 Hz, 3H), 1.35 (t, J = 7.1 Hz, 3H); 13C NMR (75 MHz, CDCb) 5 167.6,
141.1, 128.7, 128.7, 126.5, 125.9 (d, J = 10.0 Hz), 125.2 (d, J = 11.0 Hz), 63.5 (d, 
J = 5.5 Hz), 52.2, 36.2, 29.0, 16.4 (d, J = 6.5 Hz); IR (neat) 2984, 2951, 2077, 
1705, 1609, 1261, 1191, 1165, 1045, 1016, 974 cm-1; LRMS m/z calcd for 
C17H23N2OsPNa 389.1 [M+Na]+, found 389.1.
(E)-methyl 4-diazo-4-(diethoxyphosphoryl)-2-methylbut-2-enoate (2.100).
Prepared according to the general procedure using phosphonate 2.92 (14.5 mg, 
0.0343 mmol), ABSA (9.1 mg, 0.0379 mmol) and DBU (6.2 ^L, 0.041 mmol) to 
give 12.8 mg of 2.100 (83%) as a clear orange oil after flash chromatography 
(2:1 hexane/ethyl acetate).
2.100: 1H NMR (300 MHz, CDCb) 5 6.63 (d, J = 8.4 Hz, 1H), 4.26 - 4.06 (m, 4H),
3.73 (s, 3H), 3.45 (d, J = 5.9 Hz, 2H), 2.48 (dd, J = 14.3, 6.0 Hz, 1H), 2.19 (dd, J 
= 14.2, 9.0 Hz, 1H), 1.87 - 1.70 (m, 1H), 1.37 (t, J = 7.2 Hz, 3H), 1.36 (t, J = 7.1 
Hz, 3H), 0.89 (s, 9H), 0.86 (d, J = 6.6 Hz, 3H), 0.03 (s, 6H); 13C NMR (75 MHz, 
CDCb) 5 168.1, 125.8 (d, J = 10.5 Hz), 124.9 (d, J = 11.0 Hz), 68.2, 63.5 (d, J =





2954, 2930, 2857, 2075, 1708, 1607, 1472, 1435, 1260, 1210, 1090, 1048, 1019, 
973 cm-1; LRMS m/z calcd for C19H37N2O6PSiNa 471.2 [M+Na]+, found 471.1.
(E)-methyl-8-(tert-butyldimethylsNyloxy)-2-(2-diazo-2(diethoxyphosphoryl) 
ethylidene) octanoate 2.101. Prepared according to the general procedure 
using phosphonate 2.93 (0.142 g, 0.320 mmol), ABSA (83 mg, 0.35 mmol) and 
DBU (56.0 ^L, 0.375 mmol) to give 0.115 g of 2.101 (77%) as a clear orange oil 
after flash chromatography (2:1 hexane/ethyl acetate)
2.101: 1H NMR (500 MHz, CDCl3) 5 6.56 (d, J = 8.3 Hz, 1H), 4.20 - 4.10 (m, 4H),
3.72 (s, 3H), 3.58 (t, J = 6.6 Hz, 2H),), 2.33 (t, J = 7.8 Hz, 2H), 1.53 - 1.46 (m, 
2H), 1.42 - 1.30 (m, 12H), 0.88 (s, 9H), 0.03 (s, 6H); 13C NMR (125 MHz, CDCb) 
5 167.8, 127.4 (d, J = 10.2 Hz), 124.2 (d, J = 10.7 Hz), 63.5 (d, J = 5.3 Hz), 63.4,
52.1, 33.0, 30.5, 29.5, 26.7, 26.2, 25.8, 16.4 (d, J = 7.0 Hz), -5.1; IR (neat) 2930, 
2857, 2360, 2341, 2075, 1707, 1608, 1435, 1258, 1095, 1018, 973, 836, 775 cm- 
1; LRMS m/z calcd for C21H41N2O6PSi 499.2 [M+Na]+, found 499.2
(E)-methyl 4-(diethoxyphosphoryl)- 2-ethyl- 2-(3-(3-methoxy-3-oxopropyl)-
2-(phenylthio) -3H-indol-3-yl)but-3-enoate (2.60). To a solution of thioindole 





rt was added a solution of diazophosphonate 2.49 (40.0 mg, 0.138 mmol) in 
CH2Cl2 (2 mL) over 4 h via syringe pump. After stirring at rt for 24 h, the reaction 
mixture was concentrated. Flash chromatography (1:2 hexane/ ethyl acetate) 
gave 7.1 mg of indoline 2.60 (27%) as a pale yellow oil.
2.60: 1H NMR (500 MHz, CDCl3) 5 7.65 - 7.62 (m, 2H), 7.46 - 7.41 (m, 3H), 7.28 
(d, J = 7.3 Hz, 1H), 7.23 (t, J = 7.6 Hz, 1H), 7.14 (d, J = 7.3 Hz, 1H), 7.07 (dt, J =
7.3, 1.0 Hz, 1H), 6.97 (dd, J = 23.9, 18.1 Hz, 1H), 5.61 (dd, J = 18.3, 18.3 Hz, 
1H), 4.02 - 3.88 (m, 4H), 3.75 (s, 3H), 3.54 (s, 3H), 2.74 - 2.57 (m, 2H), 2.24 -
2.16 (m, 1H), 2.00 - 1.86 (m, 2H), 1.34 - 1.24 (m, 7H), 0.79 (t, J = 7.1 Hz, 3H); 
13C NMR (125 MHz, CDCb) 5 181.4, 173.3, 171.5, 155.4, 147.2 (d, J = 6.9 Hz),
138.3, 134.8, 129.7, 129.6, 129.1, 128.2, 124.5, 123.7, 121.0 (d, J = 184.6 Hz),
120.0, 68.7 (d, J = 1.5 Hz), 62.1 (d, J= 5.3 Hz), 62.0 (d, J= 5.3 Hz), 58.5 (d, J =
19.9 Hz), 52.2, 51.8, 29.0, 27.4, 24.2, 16.6, 16.5, 9.9 IR (neat) 2981, 1734, 1514, 
1456, 1441, 1250, 1213, 1170, 1052, 1023, 965, 849, 748 cm-1; LRMS m/z calcd 
for C28H35NO7PS 574.2 [M+H]+, found 574.2
2.4.3 General procedure for cyclopentene formation 
To a solution of vinyl diazophosphonate (ca. 0.10 mmol) in CH2Cl2 was 
added Rh2(OAc)4 (ca. 0.005 mmol) in one portion. After stirring at rt overnight, 
the reaction mixture was concentrated. The resulting residue was purified by 
flash chromatography to give cyclopentenes.
61
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2.4.4 General procedure for equilibration
To a solution of the cyclopentene 2.103, 2.105 or 2.106 in CH2Cl2 was added 
0.05 mL of DBU dropwise. The reaction mixture was allowed to stir for 1 h before 
it was concentrated. Preparative TLC (1:2 hexane/ethyl acetate) gave 
cyclopentenes as single isomers as determined by 1H NMR analysis in 70% ~ 80% 
yield.
Methyl 3-(diethoxyphosphoryl)cyclopent-1-enecarboxylate (2.61). Prepared 
according to the general procedure using diazo 2.59 (147 mg, 0.510 mmol) and 
Rh2(OAc)4 (11 mg, 0.025 mmol) to give 91.1 mg of cyclopentene 2.61 (68%) as a 
colorless oil after flash chromatography (1:2 to 1:3 hexane/ethyl acetate).
2.61: 1H NMR (300 MHz, CDCb) 5 6.65 (dddd, J = 4.7, 2.2, 2.2, 2.2 Hz, 1H), 4.17 
- 4.05 (m, 4H), 3.73 (s, 3H), 3.28-3.13 (m, 1H), 2.80 - 2.54 (m, 2H), 2.37 - 2.15 
(m, 2H), 1.31 (t, J = 7.0 Hz, 3H), 1.30 (t, J = 7.0 Hz, 3H); 13C NMR (75 MHz, 
CDCb) 5 165.2 (d, J = 3.0 Hz), 139.5 (d, J = 14.0 Hz), 138.4 (d, J = 9.0 Hz), 62.5 
(d, J = 7.0 Hz), 62.3 (d, J = 7.1 Hz), 51.9, 44.5 (d, J = 143.2 Hz), 31.5 (d, J = 3.5 
Hz), 24.7 (d, J = 3.0 Hz), 16.7 (d, J = 5.5 Hz); IR (neat) 2982, 1717, 1438, 1257, 







Prepared according to the general procedure using diazo 2.95 (22.3 mg, 0.0730 
mmol) and Rh2(OAc)4 (1.6 mg, 0.0037 mmol) to give 18.1 mg of cyclopentene
2.103 (89%) as a colorless oil after flashchromatography (1:2 to 1:3 hexane/ethyl 
acetate).
2.103 (after equilibration using DBU): 1H NMR (300 MHz, CDCb) 5 6.60 (dddd, J 
= 4.6, 2.2, 2.2, 2.2 Hz, 1H), 4.18 - 4.05 (m, 4H), 3.74 (s, 3H), 2.99 - 2.86 (m, 1H),
2.84 - 2.65 (m, 2H), 2.32 - 2.18 (m, 1H), 1.31 (dt, J = 7.2, 0.3 Hz 3 H), 1.30 (dt, J 
= 7.4, 0.3 Hz, 3H), 1.14 (dd, J = 6.8, 0.9 Hz, 3H); 13C NMR (75 MHz, CDCb) 5
165.3, 138.1 (d, J = 13.5 Hz), 137.5 (d, J = 9.0 Hz), 62.4 (d, J = 7.1 Hz), 62.3 (d, 
J = 6.9 Hz), 52.5 (d, J = 141.6 Hz), 51.9, 39.9 (d, J = 4.0 Hz), 33.8 (d, J = 2.0 Hz),
22.2 (d, J = 9.5 Hz), 16.7 (d, J = 5.6 Hz); IR (neat) 2959, 1718, 1635, 1438, 1249, 






(2.104). Prepared according to the general procedure using diazo 2.96 (11.8 mg, 
0.037 mmol) and Rh2(OAc)4 (0.8 mg, 0.0018 mmol) to give 9.3 mg of 
cyclopentene 2.104 (86%) as a colorless oil after flash chromatography (1:2 to 
1:3 hexane/ethyl acetate).
2.104: 1H NMR (300 MHz, CDCb) 5 6.64 - 6.59 (m, 1H), 4.18 - 4.02 (m, 4H), 3.73 
(s, 3H), 2.82 (dddd, J = 25.8, 2.6, 2.6, 1.6 Hz, 1H), 2.58 (dddd, J = 16.1, 6.9, 2.3,
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2.3 Hz, 1H), 2.37 (dddd, J = 16.2, 7.4, 1.6, 1.6 Hz, 1H), 1.34 - 1.27 (m, 9H), 1.18 
(d, J = 1.2 Hz, 3H); 13C NMR (75 MHz, CDCb) 5 165.4 (d, J = 3.0 Hz), 138.7 (d, J 
= 9.5 Hz), 137.9 (d, J = 13.1 Hz), 62.1 (d, J = 7.0 Hz), 62.0 (d, J = 7.5 Hz), 55.1 
(d, J = 138.7 Hz), 51.8, 46.7 (d, J = 2.6 Hz), 42.3, 31.3 (d, J = 10.5 Hz), 25.6 (d, J 
= 5.5 Hz), 16.7 (d, J = 6.0 Hz); IR (neat) 2980, 1718, 1437, 1247, 1164, 1053, 




Prepared according to the general procedure using diazo 2.98 (15.7 mg, 0.0496 
mmol) and Rh2(OAc)4 (1.1 mg, 0.0025 mmol) to give 11.9 mg of cyclopentene
2.105 (83%) as a colorless oil after flash chromatography (1:2 to 1:3 
hexane/ethyl acetate).
2.105 (after DBU equilibration): 1H NMR (500 MHz, CDCb) 5 6.62 - 6.60 (m, 1H),
5.85 (ddd, J = 17.6, 10.3, 7.8 Hz, 1H), 5.12-5.08 (m, 1H), 5.01 (d, J = 10.3 Hz, 
1H), 4.15 - 4.07 (m, 4H), 3.74 (s, 3H), 3.35 - 3.25 (m, 1H), 3.04 (ddd, J = 7.9, 5.4,
3.2 Hz, 1H), 3.00-2.93 (m, 1 H), 2.55 - 2.48 (m, 1H), 1.32 (t, J = 7.1 Hz, 3H), 1.30 
(t, J = 7.1 Hz, 3H); 13C NMR (125 MHz, CDCb) 5 165.0 (d, J = 3.1 Hz), 140.5 (d, 
J = 8.4 Hz), 138.0 (d, J = 13.7 Hz), 137.4 (d, J = 9.2 Hz), 114.7 (d, J = 2.3 Hz),
62.6 (d, J = 7.0 Hz), 62.4 (d, J = 6.9 Hz), 51.9, 50.7 (d, J = 142.7 Hz), 42.7 (d, J =
2.3 Hz), 37.9 (d, J = 3.8 Hz), 16.7 (d, J = 1.5 Hz), 16.7 (d, J = 2.3 Hz); IR (neat) 
2982, 1719, 1635, 1438, 1249, 1096, 1053, 1024, 962 cm-1; LRMS m/z calcd for 
C13H21N2OsPNa 311.1 [M+Na]+, found 311.1.
O




Prepared according to the general procedure using diazo 2.99 (17.6 mg, 0.0480 
mmol) and Rh2(OAc)4 (1.1 mg, 0.0024 mmol) to give 11.9 mg of cyclopentene
2.106 (78%) as a colorless oil after flash chromatography (1:2 to 1:3 
hexane/ethyl acetate).
2.106 (after DBU equilibration): 1H NMR (300 MHz, CDCb) 5 7.33 - 7.16 (m, 5H),
6.72 (dddd, J = 6.2, 2.3, 2.3, 2.3 Hz, 1H), 4.13 - 3.98 (m, 4H), 3.90 - 3.77 (m, 1H), 
3.77 (s, 3H), 3.35 - 3.16 (m, 2H), 2.86 - 2.72 (m, 1H), 1.25 (t, J = 7.0 Hz, 6H); 13C 
NMR (125 MHz, CDCl3) 5 164.9 (d, J = 3.0 Hz), 145.5 (d, J = 8.4 Hz), 138.2 (d, J 
= 13.7 Hz), 137.4 (d, J = 8.4 Hz), 129.0, 127.1, 126.9, 62.6 (d, J = 6.9 Hz), 62.4 
(d, J = 6.9 Hz), 53.6 (d, J = 141.9 Hz), 51.9, 44.1 (d, J = 1.5 Hz), 40.8 (d, J = 4.6 
Hz), 16.7 (d, J = 6.1 Hz), 16.6 (d, J = 6.1 Hz); IR (neat) 2983, 2951, 1718, 1634, 
1495, 1438, 1391, 1349, 1250, 1195, 1162, 1097, 1023 cm-1; LRMS m/z calcd for 
C17H23OsPNa 361.1 [M+Na]+, found 361.0.
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Summary of 1D NOE data for the single isomer of compound 2.106 after 
equilibration (500 Hz, C6D6):
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Irradiation at 2.80 ppm (H-1) resulted in enhancement at 3.30 ppm (H-3) and
7.05 ppm (H-5);
Irradiation at 3.30 ppm (H-3) resulted in enhancement at 2.80 ppm (H-1); 
Irradiation at 3.20 ppm (H-2) resulted in enhancement at 7.05 ppm (H-5), 6.85 
ppm (H-6), 3.80 ppm (H-4) and 2.80 ppm (H-1);




methyl cyclopent-1-enecarboxylate (2.107). Prepared according to the general 
procedure using diazo 2.100 (93.1 mg, 0.208 mmol) and Rh2(OAc)4 (4.6 mg, 
0.010 mmol) to give 79.0 mg of cyclopentene 1.180 (91%, 3:2 mixture of isomers) 
as a colorless oil after flash chromatography (1:2 to 1:3 hexanes/ethyl acetate). 
Analytically pure 2.107 (major isomer) was obtained following preparatory TLC 
(1:2 hexanes/ethyl acetate). The minor isomer could not be separated from the 
major isomer.
2.107 (major isomer): [a] d 25 = -48.0 (c = 0.125, CHCb) 1H NMR (300 MHz, 
CDCb) 5 6.63 - 6.60 (m, 1H), 4.15 - 4.04 (m, 4H), 3.82 (d, J = 9.8 Hz, 1H), 3.74 
(s, 3H), 3.70 (d, J = 8.8 Hz, 1H), 2.89 - 2.78 (m, 2H), 2.32 (dddd, J = 17.1, 7.8,
2.0, 2.0 Hz,1H), 1.31 (t, J = 7.1 Hz, 6H), 1.21 (broad s, 3H), 0.90 (s, 9H), 0.04 (s, 
6H); 13C NMR (75 MHz, CDCb) 5 165.5, 138.0 (d, J = 9.1 Hz), 137.9, 67.8 (d, J =
67
6.0 Hz), 62.3 (d, J = 7.1 Hz), 62.0 (d, J = 7.6 Hz), 53.6 (d, J = 137.6 Hz), 51.8, 
47.8, 42.2 (d, J = 3.0 Hz), 26.1, 25.8 (d, J = 9.6 Hz), 18.5, 16.7 (d, J = 6.0 Hz), -
5.2 (d, J =1.5 Hz); IR (neat) 2954, 2929, 2856, 1721, 1472, 1438, 1249, 1198, 
1086, 1053, 1027 cm-1; LRMS m/z calcd for C19H37O6PSiNa 443.2 [M+Na]+, 
found 443.1.
Complete chirality retention in C-H insertion reactions is identified by HPLC 
separation of compound 28 (chiral OD-H column, 0.5 ml/min, 98:2 
hexane/isopropanol)
28 from racemic diazo 18: tR = 7.92 min (50%), 24.68 (50%)
28 from chiral diazo 18: tR = 7.80 min
cyclopent-1-enecarboxylate 2.108. Prepared according to the general 
procedure using diazo 2.101 (0.115 g, 0.242 mmol) and Rh2(OAc)4 (5.4 mg, 
0.012 mmol) to give 0.102 g of cyclopentene 2.108 (94%) as a colorless oil after 
flash chromatography (1:2 hexane/ethyl acetate).
2.108: 1H NMR (500 MHz, CDCb) 5 6.60 - 6.57 (m, 1H), 4.14 - 4.05 (m, 4H), 3.73 
(s, 3H), 3.58 (t, J = 6.6 Hz, 2H),), 2.92 - 2.80 (m, 2H), 2.70 - 2.57 (m, 1H), 2.35 -
2.27 (m, 1H), 1.56 - 1.47 (m, 3H), 1.40 - 1.27 (m, 9H), 0.87 (s, 9H), 0.03 (s, 6H); 
13C NMR (75 MHz, CDCb) 5 165.3, 138.2 (d, J = 13.3 Hz), 137.5 (d, J = 9.6 Hz),
63.2, 62.4 (d, J = 7.3 Hz), 62.3 (d, J = 6.9 Hz), 51.8, 50.8 (d, J = 142.4 Hz), 38.8 




J = 5.5 Hz), -5.0; IR (neat) 2931, 2857, 2361, 2340, 1718, 1436, 1252, 1096, 
1025, 959, 836, 775 cm-1; LRMS m/z calcd for C21H41O6PSi 449.2 [M+H]+, found
449.2
Methyl 1-(diethoxyphosphoryl)bicyclo[3.1.0]hex-2-ene-3-carboxylate (2.109).
To a solution of vinyl diazophosphonate 2.97 (20.0 mg, 61.7 ^mol) in CH2Cl2 (2 
mL) was added Cu(CH3CN)4PF6 (1.2 mg, 3.2 ^mol) in one portion. After stirring 
for 5 min the reaction mixture was concentrated and flash chromatography (1:2 
hexane/ethyl acetate) provided 14.9 mg of desired product 2.109 (82%) as a 
colorless oil.
2.109: 1H NMR (500 MHz, CDCl3) 5 6.86 (dt, J = 1.9 Hz, 1H), 4.17 - 4.00 (m, 4H),
3.70 (s, 3H), 2.89 (ddt, J = 18.0, 5.2, 1.8 Hz, 1H), 2.70 (dd, J = 18.1, 9.1 Hz, 1H), 
2.33 - 2.22 (m, 1H), 1.67 (ddd, J = 13.2, 8.2, 4.0 Hz, 1H), 1.33 (t, J = 7.1 Hz, 3H),
1.28 (t, J = 7.0 Hz, 3H), 0.59 (q, J = 5.0 Hz, 1H); 13C NMR (75 MHz, CDCb) 5
165.2, 143.7 (d, J = 6.5 Hz), 135.3 (d, J = 122.1 Hz), 62.4 (d, J = 6.1 Hz), 51.8,
34.6, 29.8 (d, J = 205.0 Hz), 23.9 (d, J = 3.0 Hz), 22.8, 16.7 (d, J = 6.1 Hz), 16.6 
(d, J = 6.0 Hz); IR (neat) 2984, 2920, 1718, 1617, 1438, 1249, 1025, 964, 942 






Prepared according to the general procedure using phosphonocrotonate 2.56 
(0.236 g, 1.00 mmol), THF (5 mL), LiHMDS (1.0 mL of a 1.0 M solution in THF,
1.0 mmol) and cyclohexylmethyl trifluoromethanesulfonate (0.169g, 0.686 mmol) 
in THF (2 mL) to give 0.142 g of 2.118 (59%) as a colorless oil after flash 
chromatography (1:2 hexanes:ethyl acetate).
2.118: 1H NMR (300 MHz, CDCb) 5 6.77 (q, J = 7.9 Hz, 1H), 4.17 - 4.05 (m, 4H),
3.72 (s, 3H), 2.72 (dd, J = 23.3, 8.1 Hz, 2H), 2.21 (dd, J = 7.1, 1.7 Hz, 2H), 1.70 - 
1.57 (m, 5H), 1.44 - 1.34 (m, 1H), 1.30 (t, J = 7.1 Hz, 6H), 1.20 - 1.07 (m, 3H), 
0.93 - 0.84 (m, 2H); 13C NMR (125 MHz, CDCb) 5 168.1 (d, J = 2.3 Hz), 135.2 (d, 
J = 14.5 Hz), 131.3 (d, J = 10.7 Hz), 62.4 (d, J = 6.7 Hz), 52.1, 37.9 (d, J = 2.3 
Hz), 34.5, 33.4, 27.9 (d, J = 139.6 Hz), 26.6, 26.5, 16.6 (d, J = 6.1 Hz); IR (neat)
2982, 2923, 2851, 2360, 2340, 1716, 1645, 1448, 1249, 1024, 963, 820 cm-1; 
LRMS m/z calcd for C16H29O5P 355.2 [M+Na]+, found 355.2
enoate 2.119. Prepared according to the general procedure using phosphonate 
2.118 (41 mg, 0.12 mmol), ABSA (32 mg, 0.13 mmol) and DBU (22 |jL, 0.15 
mmol) to give 36 mg of 2.119 (82%) as a clear orange oil after flash 




2.119: 1H NMR (500 MHz, CDCb) 5 6.59 (d, J = 8.3 Hz, 1H), 4.22 - 4.08 (m, 4H),
3.72 (s, 3H), 2.23 (d, J = 7.3 Hz, 2H), 1.72 - 1.60 (m, 6H), 1.36 (t, J = 7.1 Hz, 
6H), 1.22 - 1.10 (m, 3H), 0.96 - 0.86 (m, 2H); 13C NMR (125 MHz, CDCb) 5 168.1,
126.2 (d, J = 10.7 Hz), 124.6 (d, J = 11.2 Hz), 63.5 (d, J = 5.4 Hz), 52.1, 38.8 (d, 
J = 2.7 Hz), 33.4, 32.9, 26.6 (d, J = 3.6 Hz), 16.4 (d, J = 6.9 Hz); IR (neat) 2984, 
2924, 2851, 2360, 2341, 2071, 1705, 1604, 1435, 1262, 1016, 972, 753 cm-1; 
LRMS m/z calcd for C16H27N2O5P 381.2 [M+Na]+, found 381.2
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Methyl 4-(diethoxyphosphoryl)spiro[4.5]dec-2-ene-2-carboxylate 2.120. Prepared 
according to the general procedure using diazo 2.119 (29.9 mg, 0.083 mmol) and 
Rh2(OAc)4 (1.8 mg, 4.2 ^mol) to give 24.0 mg of cyclopentene 2.120 (89%) as a 
colorless oil after flash chromatography (1:2 hexane/ethyl acetate).
2.120: 1H NMR (500 MHz, CDCb) 5 6.62 - 6.60 (m, 1H), 4.14 - 4.03 (m, 4H), 3.73 
(s, 3H), 2.80 (dd, J = 15.9, 2.8 Hz, 1H), 2.56 (d, J = 7.8 Hz, 2H), 1.92 - 1.86 (m, 
1H), 1.78 (dt, J = 12.5, 3.3 Hz, 1H), 1.67 (td, J = 13.0, 3.9 Hz, 1H), 1.62 - 1.50 (m 
3H), 1.50 - 1.40 (m, 3H), 1.36 - 1.20 (m, 8H); 13C NMR (125 MHz, CDCb) 5 165.5 
(d, J = 3.8 Hz), 138.7 (d, J = 10.0 Hz), 137.6 (d, J = 13.0 Hz), 62.0 (d, J = 6.9 Hz),
61.9 (d, J = 7.6 Hz), 56.3 (d, J = 137.3 Hz), 51.8, 46.4, 41.2, 38.2 (d, J = 11.5 Hz),
34.3 (d, J = 6.1 Hz), 26.0, 23.6, 23.0, 16.7 (d, J = 3.8 Hz), 16.7 (d, J = 4.6 Hz); IR 
(neat) 2981, 2928, 2855, 1716, 1635, 1437, 1245, 1051, 1024, 957, 742 cm-1; 




Prepared according to the general procedure using phosphonocrotonate 2.56 
(0.236 g, 1.00 mmol), THF (5 mL), LiHMDS (1.0 mL of a 1.0 M solution in THF,
1.0 mmol) and cycloheptylmethyl trifluoromethanesulfonate (0.159g, 0.610 mmol) 
in THF (2 mL) to give 0.116 g of 2.122 (55%) as a colorless oil after flash 
chromatography (1:2 hexanes:ethyl acetate).
2.122: 1H NMR (300 MHz, CDCl3) 5 6.78 (q, J = 7.9 Hz, 1H), 4.16 - 4.05 (m, 4H),
3.74 (s, 3H), 2.74 (dd, J = 22.9, 8.1 Hz, 2H), 2.27 - 2.21 (m, 2H), 1.72 - 1.24 (m, 
17H), 1.19 - 1.06 (m, 2H); 13C NMR (125 MHz, CDCl3) 5 168.1 (d, J = 3.2 Hz),
135.7 (d, J = 14.4 Hz), 131.3 (d, J = 10.2 Hz), 62.4 (d, J = 6.4 Hz), 52.1, 39.5 (d, 
J = 2.7 Hz), 34.9 (d, J = 2.1 Hz), 34.6, 28.5, 27.9 (d, J = 139.4 Hz), 26.3, 16.6 (d, 
J = 6.4 Hz); IR (neat) 2982, 2921, 2853, 2359, 2341, 1715, 1645, 1437, 1254, 




enoate 2.123. Prepared according to the general procedure using phosphonate 
2.122 (54 mg, 0.16 mmol), ABSA (42 mg, 0.17 mmol) and DBU (28 |jL, 0.19
72
mmol) to give 48 mg of 2.123 (83%) as a clear orange oil after flash 
chromatography (2:1 hexane/ethyl acetate).
2.123: 1H NMR (500 MHz, CDCb) 5 6.59 (d, J = 8.3 Hz, 1H), 4.22 - 4.08 (m, 4H),
3.72 (s, 3H), 2.26 (d, J = 7.3 Hz, 2H), 1.68 - 1.52 (m, 7H), 1.50 - 1.42 (m, 2H),
1.38 - 1.30 (m, 8H), 1.18 - 1.10 (m, 2H), 0.96 - 0.86 (m, 2H); 13C NMR (125 MHz, 
CDCb) 5 168.1, 126.6 (d, J = 10.4 Hz), 124.7 (d, J = 11.2 Hz), 63.5 (d, J = 5.3 
Hz), 52.1, 40.4, 34.3, 34.0, 28.4, 26.6, 16.4 (d, J = 6.9 Hz); IR (neat) 2984, 2922,
2853, 2360, 2341, 2070, 1704, 1603, 1436, 1261, 1015, 971, 760 cm-1; LRMS 
m/z calcd for C17H29N2O5P 395.2 [M+Na]+, found 395.2
2.124
Methyl 4-(diethoxyphosphoryl)spiro[4.6]undec-2-ene-2-carboxylate 2.124.
Prepared according to the general procedure using diazo 2.123 (43 mg, 0.11 
mmol) and Rh2(OAc)4 (2.5 mg, 5.7 ^mol) to give 34 mg of cyclopentene 2.124 
(86%) as a colorless oil after flash chromatography (1:2 hexane/ethyl acetate). 
2.124: 1H NMR (500 MHz, CDCb) 5 6.62 - 6.60 (m, 1H), 4.14 - 4.02 (m, 4H), 3.72 
(s, 3H), 2.84 (d, J = 25.9 Hz, 1H), 2.58 (dd, J = 16.1, 7.8 Hz, 2H), 2.47 (dd, J =
16.6, 7.6 Hz, 1H), 2.13 (dd, J = 14.5, 9.5 Hz, 1H), 1.81 (dd, J = 14.4, 8.1 Hz, 1H),
1.71 (dd, J = 13.9, 8.1 Hz, 1H), 1.66 - 1.36 (m, 9H), 1.33 - 1.22 (m, 6H); 13C NMR 
(125 MHz, CDCb) 5 165.5, 139.2 (d, J = 10.7 Hz), 137.7 (d, J = 13.0 Hz), 62.1 (d, 
J = 7.6 Hz), 62.0 (d, J = 6.9 Hz), 56.7 (d, J = 136.6 Hz), 51.8, 49.8, 44.3, 42.6(d, 
J = 12.2 Hz), 36.4 (d, J = 5.3 Hz), 29.9 (d, J = 7.6 Hz), 24.1, 23.0, 16.7 (d, J = 2.3
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Hz), 16.7 (d, J = 2.3 Hz); IR (neat) 2980, 2921, 2853, 1715, 1635, 1437, 1241, 
1051, 1022, 957, 740 cm-1; LRMS m/z calcd for C17H29O5P 367.2 [M+H]+, found
367.1
enecarboxylate 2.125. To a solution of cyclopentene 2.108 (0.274 g, 0.611 
mmol) in 190 proof ethanol (5 mL) at rt was added PPTS (0.153 g, 0.612 mmol) 
in one portion. The reaction mixture was allowed to react at rt for 6 h. 
Concentrate and flash chromatography (10:1 ethyl acetate/ethanol) provided
0.191 g of alcohol 2.125 (94%) as a colorless oil.
2.125: 1H NMR (500 MHz, CDCb) 5 6.59 - 6.55 (m, 1H), 4.15 - 4.04 (m, 5H), 3.72 
(s, 3H), 3.62 (dt, J = 6.2, 1.1 Hz, 2H), 2.94 - 2.81 (m, 2H), 2.64 - 2.60 (m, 1H), 
2.36 - 2.26 (m, 1H), 1.96 (br, 1H), 1.58 - 1.48 (m, 3H), 1.41 - 1.33 (partially 
obscure, m, 2H), 1.30 (t, J = 7.0 Hz, 3H), 1.29 (t, J = 7.1 Hz, 3H); 13C NMR (125 
MHz, CDCb) 5 165.2, 138.1 (d, J = 13.0 Hz), 137.4 (d, J = 9.2 Hz), 62.5 (d, J =
6.9 Hz), 62.4 (d, J = 6.1 Hz), 51.8, 50.7 (d, J = 142.7 Hz), 38.5, 37.9 (d, J = 3.1 
Hz), 36.4 (d, J = 8.4 Hz), 32.6, 23.5, 16.7 (d, J = 5.3 Hz); IR (neat) 3413, 2931, 
2859, 1717, 1635, 1438, 1237, 11051, 1021, 963 cm-1; LRMS m/z calcd for 







2.126. To a solution of alcohol 2.125 (25 mg, 0.073mmol) in CH2Cl2 (3 mL) at rt 
was added DMP (93 mg, 0.22 mmol) in one portion. The reaction mixture was 
allowed to react at rt for 4 h. The reaction was quenched with NaHCO3 (aq., 5 mL) 
and separated. The aqueous phase was extracted with 5 mL EtOAc three times 
and the combined organic phase was dried and concentrated. Flash 
chromatography (1:20 hexane/ethyl acetate) provided 22 mg of aldehyde 2.126 
(88%) as a colorless oil.
2.126: 1H NMR (500 MHz, CDCb) 5 9.75 (s, 1H), 6.57 - 6.57 (m, 1H), 4.13 - 4.06 
(m, 4H), 3.72 (s, 3H), 2.92 - 2.83 (m, 1H), 2.67 - 2.59 (m, 1H), 2.45 (t, J = 6.4 Hz, 
2H), 2.35 - 2.29 (m, 1H), 1.69 - 1.52 (m, 3H), 1.43 - 1.35 (partially obscure, m, 
2H), 1.30 (t, J = 6.8 Hz, 3H), 1.29 (t, J = 7.3 Hz, 3H); 13C NMR (125 MHz, CDCb) 
5 202.2, 165.1, 138.1 (d, J = 13.4 Hz), 137.4 (d, J = 9.2 Hz), 62.5 (d, J = 6.7 Hz),
62.4 (d, J = 7.3 Hz), 51.9, 50.7 (d, J = 143.4 Hz), 43.8, 38.6 (d, J = 2.5 Hz), 37.9 
(d, J = 3.7 Hz), 36.0 (d, J = 10.2 Hz), 19.8, 16.7 (d, J = 6.1 Hz); IR (neat) 2929.
2854, 1719, 1633, 1440, 1247, 1052, 1023, 962 cm-1; LRMS m/z calcd for 
C15H2O6P 330.1[M+H]+, found 330.1
2.127
Methyl 5,6,7,7a-tetrahydro-1H-indene-2-carboxylate (2.127). To a solution of 
aldehyde 2.126 (23.0 mg, 0.0699 mmol) in THF (3 mL) at 0 oC was added 
NaHMDS (0.10 mL, 1M solution in THF, 0.10 mmol) dropwise. The reaction 
mixture was allowed to react at 0 oC for 10 min. Concentrate and flash 
chromatography provided 8.1 mg of 2.127 (65%) as a colorless oil.
2.127: 1H NMR (500 MHz, CDCl3) 5 6.97 (s, 1H), 5.75 (dt, J = 3.0 Hz, 1H), 3.74 
(s, 3H), 2.78 (dd, J = 15.2, 8.4 Hz, 1H), 2.73 - 2.62 (m, 1H), 2.28 - 2.13 (m, 3H),
2.10 - 2.02 (m, 1H), 1.89 - 1.84 (m, 1H). 1.64 - 1.68 (m, 1H), 1.35 - 1.22 (m, 1H); 
13C NMR (125 MHz, CDCb) 5 166.4, 147.0, 141.7, 137.0, 123.3, 51.4, 40.1, 36.9,
28.1, 25.3, 22.5; IR (neat) 2926, 2854, 1714, 1653, 1587, 1436, 1244, 1086 cm-1; 
LRMS m/z calcd for CnH14O2Na 201. 1 [M+Na]+, found 201.1.
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CHAPTER 3
DIAZO VINYL PHOSPHONATES AS PRECURSORS TOWARDS 
THE SYNTHESIS OF DYSIHERBAINE ANALOGS
3.1 Synthesis of diazo vinyl phosphonate 
In our effort to prepare malonate derived diazo phosphonate 3.5, acylation of 
phosphonocrotonate 3.1 with methyl chloroformate 3.2 provided an inseparable 
mixture of the desired acylation product 3.3 and starting material 3.1 (Scheme 
3.1). When subjecting this mixture to diazo transfer condition using tosyl azide as 
the diazo transfer reagent, surprisingly, diazo vinyl phosphonate 3.4 was 
obtained in good yield.
We were very excited about this result because it indicated that diazo 
compound directly derived from phosphonocrotonate 3.1 was actually accessible. 
The fact that the diazo functionality was formed solely adjacent to the ester group 
was confirmed by 13C NMR. Higher yield was achieved by directly treating 
phosphonocrotonate 3.1 with TsN3 and DBU (Scheme 3.2). The resulting diazo 
compound 3.4 was quite stable as it could be stored in benzene at -30 oC for a 
month. Upon heating, the diazo vinyl phosphonate 3.4 readily formed diazine 3.6 
in good yield.
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At this stage, we revisited the diazo transfer reaction of phosphonocrotonate
3.1 using ABSA as the diazo transfer reagent (Scheme 3.3). Crude NMR clearly 
showed that the desired diazo vinyl phosphonate 3.4 was formed; however, 
because diazo 3.4, ABSA and the side product 4-acetamidobenzenesulfonamide 
had the same Rf value, further purification was not trivial. In the end, we were 
able to separate the desired product 3.4 from ABSA and sulfonamide taking 
advantage of their differences in solubility. After flash chromatography, washing 
the diazo compound/sulfonamide/ABSA coelute with a minimal amount of 
chloroform provided pure diazo 3.4 as indicated by 1H NMR, although the yield 
was much lower than that using TsN3 as diazo transfer reagent. The difficult 
purification and the limited stability of the diazo compound are probably the 
reason why we were not able to identify the desired diazo product previously.
Phosphonate is generally recognized as an electron-withdrawing group, so 
this new diazo ester is considered to be an acceptor-acceptor type diazo 
compound. However, the electron-withdrawing effect of a phosphonate is much 
weaker than a corresponding ester, as indicated by the acidity of their a-proton: 
pKa of the a-proton of malonate 3.7 is 15.7 while the pKa of the a-proton of 
phosphonoester 3.8 is 18.6 (Scheme 3.4).1 Interestingly, the pKa of the a-proton 
of the benzyl ester 3.9 is only 23.6 and the corresponding metal carbenoid is 
considered to be a donor-acceptor carbenoid, it suggests that the reactivity of the 
metal carbenoid derived from diazo vinyl phosphonate 3.4 might fall between the 
traditional acceptor-acceptor metal carbenoids and the donor-acceptor 
carbenoids.
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Scheme 3.3 Synthesis of vinyl diazo phosphnate using ABSA
3.2 X-H Insertions of diazo vinyl phosphonates
3.2.1 Introduction
Given its long history, X-H insertion of metal carbenoids where X is oxygen, 
nitrogen or sulfur haven’t received much attention from the synthetic community.2 
The reason might be that synthesis of a-functionalized carbonyl compounds can 
be accomplished by classic nucleophilic substitution reactions. However, 
compared to traditional methods, X-H insertions have several advantages. X-H 
insertions take place using mild and neutral conditions allowing a number of 
functional groups to be tolerated. The utilization of rhodium catalysts in X-H 
insertions provides very high turnovers. Compared to other transformations of 
metal carbenoids such as C-H insertions or cyclopropanations, X-H insertions 
are the preferred process.
An early milestone that illustrated the synthetic utility of X-H insertion of metal 
carbenoids was Merck’s total synthesis of thienamycin in 1980 (Scheme 3.5).3 
The pyrrolidine 3.11 was formed by an intramolecular N-H insertion in essentially 
quantitative yield. This example showcased the competency of the N-H insertion 
reaction in constructing highly strained and complex ring systems.
The Yang group reported the total synthesis of Maoecrystal V where an 
intramolecular O-H insertion was applied to assemble the key intermediate 3.14 
(Scheme 3.6).4 When treated with Rh2(OAc)4, diazo phosphonate 3.13 
underwent a chemoselective O-H insertion reaction to give seven-membered 
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Scheme 3.5 Merck's total synthesis o f (+)-Thienamycin
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Scheme 3.6 Yang's total synthesis of Maoecrystal V
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3.2.2 O-H Insertion of diazo vinyl phosphonates
To explore the ability of diazo vinyl phosphonate 3.4 to undergo X-H 
insertions, we first tested its reaction with n-butyl alcohol (Scheme 3.7). To our 
delight this reaction proceeded very efficiently in the absence of a syringe pump 
for slow addition, giving the O-H insertion product in 80% yield. Furthermore, this 
reaction was highly stereoselective as only the Z-enol ether isomer was formed 
as determined by NOE experiment. This result suggested that Z-vinyl ethers 
could be prepared via an O-H insertion of metal carbenoids derived from diazo 
phosphonate 3.4.
We next investigated the substrate scope of the O-H insertion reaction 
(Scheme 3.8). Secondary alcohols such as isopropanol underwent smooth O-H 
insertion and gave desired vinyl ether 3.18 in 84% yield. Allyl alcohol also 
participated in the O-H insertion to realize 3.19 and notably no cyclopropanation 
or C-H insertion product was formed. Similarly, highly chemoselective O-H 
insertions took place when homoallyl alcohol and alkynyl alcohols were 
evaluated. In addition, phenol reacted with vinyl diazo phosphonate and provided 
compound 3.25 in good yield. Iodo- and bromohydrins were also examined and 
the O-H insertion products 3.26 and 3.27 were isolated.
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Scheme 3.8 O-H insertion: substrate scope
When a tertiary alcohol 1,1-dimethyl propargyl alcohol 3.29 was utilized, only 
a complex mixture was formed (Scheme 3.9). We suspect that competing ylide 
formation and subsequent transformations were involved.5
In all of the experiments described in Scheme 3.8, two equivalents of 
alcohols relative to the diazo compound were used. Catalyst loading was 
between 2 mol% and 0.2 mol%. In this way, we have developed a rapid and 
efficient route towards a diverse array of Z-vinyl ethers.
3.2.3 N-H Insertion of diazo vinyl phosphonates
Inspired by the successful O-H insertion reactions, we next explored other X- 
H insertion reactions. We first focused on N-H insertions (Scheme 3.10). When 
tert-butyl carbamate was treated with diazo vinyl phosphonate 3.4 in the 
presence of Rh2(OAc)4, desired N-H insertion product 3.31 was formed in good 
yield as a single isomer. NOE experiment confirmed the Z-geometry of the 
double bond which is consistent with the O-H insertion results. The metal 
carbenoid also inserted into the more electron-deficient N-H bond of 
toluenesulfonamide to realize enamine 3.32. When acetamide was used, 
elevated reaction temperatures had to be applied, presumably in order to break 
the coordination of acetamide with the rhodium catalyst. We were also able to 
incorporate aniline into the phosphonate to give product 3.34. A very interesting 
substrate turned out to be N-Boc guanidine. The N-H insertion with guanidine in 
the presence of Rh2(OAc)4 only resulted in recovery of the starting material. In 
our previous experiments Rh2(esp)2 catalyst was a more efficient catalyst and
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more robust against substrate binding. 4A molecular sieves were also added to 
remove the methanol generated in the subsequent in situ cyclization. Using these 
optimized conditions we successfully obtained the cyclic guanidine product 3.35 
in 56% yield. This product was characterized as the reduced product 3.36 which 
was formed by treating 3.35 with Pd/C under a H2 atmosphere. It is worthwhile to 
mention that once converted to phosphonic acids, these N-H insertion products 
in physiological pH resemble glutamate, which is an important neurotransmitter.6
3.2.4 S-H Insertion of diazo vinyl phosphonates 
We also carried out the S-H insertion reaction of thiophenol to give product
3.38 in good yield (Scheme 3.11).
3.2.5 Competition study of X-H insertion reactions 
As mentioned earlier, compared to C-H insertion and cyclopropanation, X-H 
insertion is the preferred pathway for diazo decomposition. Our preliminary data 
supported this conclusion, as for all substrates the X-H insertion product was the 
only isolated product. We also wondered whether there was an inherent trend of 
reactivity within different X-H bonds and carried out additional competition 
studies (Scheme 3.12). Interestingly, when diazo 3.4 was treated with equal 
amount of aniline and phenol (one equivalent each), only aniline insertion product
3.38 was formed. In another case, n-butyl alcohol was a superior substrate 
compared to acetamide. These results indicate that selective X-H insertion in the 
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Scheme 3.12 Competition study
3.3 Intramolecular Cyclizations of the O-H insertion products
3.3.1 Introduction
We have successfully demonstrated that X-H insertion reaction of diazo vinyl 
phosphonates can serve as a convenient and efficient tool for the stereoselective 
construction of enol ethers, enamines and vinyl sulfides. One straightforward 
target was L-2-amino-4-phosphonobutanoic acid (L-AP4).6 L-AP4 has been 
shown to be a potent Group III metabotropic glutamate receptor agonist. 
Presumably, reduced product 3.42 could serve as a precursor to form L-AP4 
through functional group manipulations (Scheme 3.13).
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We envisioned that subsequent transformations on the insertion products 
could be carried out in order to further amplify their synthetic utility. The synthesis 
of heterocycles such as furans and oxetanes by intramolecular cyclizations of 
similar a-alkoxy esters has been reported by the Fujisawa and Bull groups, 
respectively (Scheme 3.14).7
We believe that the phosphonocrotonate system is facile to base 
deprotonation and provides a very good nucleophile. In particular, it will react 
with a tethered electrophile to form heterocycles (Scheme 3.15). Since the anion 
of the phosphonocrotonate can reside at either of the two positions as shown in 
3.52 and 3.54, it would be interesting to see which anion is the preferred reactive 
species in the cyclizations.
3.3.2 Synthesis of dihydrofurans via cyclization of propargyl vinyl ethers 
Although we planned to test the intramolecular cyclization, the first piece of 
useful information came from an unexpected result. We previously demonstrated 
that allyl substrates 3.19 underwent Claisen rearrangement under thermal 
conditions and a-ketoester 3.56 was formed (Scheme 3.16). When we tried to 
apply the same conditions to a similar propargyl substrate 3.21 in hope of 
obtaining the corresponding allenyl a-ketoester, only a complex mixture was 
formed. The Kirsch group have reported that when treating 3.57 with silver triflate 
and DBU, pyran 3.58 was formed via a Claisen rearrangement-6n 
electrocyclization cascade mechanism (Scheme 3.17).8 When these conditions 
were applied to 3.21, to our surprise, dihydrofuran 3.61 was formed in 91% yield.
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Scheme 3.13 Synthetic efforts towards L-AP4
Fujisawa's synthesis of tetrahydrofurans
MeV ^ C°2*_Bu _ Me C02f-Bu
1 LDA, THF, -78 °C - 0 °C iP n * ^ ~ ^ . C 0 2f-Bu iP r ^ ^ ~ y , M e
iP r^  JO"C (85%, cis/trans = 2.5:1)Br 3.45 3.46
3.44 c/s trans
Bull's synthesis of oxetanes
EtOzC,__ .C02Et Ph Rh2(OAc)4 (0.5 mol%) Et02C> .C02Et
(T  +  X  B r  --------------------------------------------- ►  *














y-0Et X, i^ E
o o
ii .OEt ii OEt 
“ ^ y ^ ' O E t  ____ ^  " ^ ^ Y ^ Y ^ O E t
X j WE
— ’ **v OEt Base " H i
X j  v E ^  3.52 3.53
'n
O O 
Me02C ^ ^ P ' ° E[ ------- ^  Me02C ^ 5 s ^P C °E]
x t * E xV fE* 'n  w n
3.54 3.55
Scheme 3.15 Proposed cyclization pathway
O
n„OEt
M8° 2CY ^ P ' 0 Et
\









Me°2c Y ^ p>0E, 80 °C, toluene
►  mixture
3.21
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Scheme 3.17 Cyclization with AgSbF6/DBU
The reaction conditions to form 3.61 were further optimized (Table 3.1). 
Although cyclization with ZnCl2 was unproductive, the AgSbF6 catalyst could be 
replaced by the less expensive and more robust AgNO3 catalyst. Utilization of a 
stronger base such as f-BuOK led to diminished yield presumably due to 
decomposition. Acetone proved to be a superior solvent for this reaction in terms 
of reaction rate and yield. A catalytic amount of DBU could be used, but the 
reaction rate decreased dramatically.
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entry Lewis acid (eq) base (eq) solvent temp time yield
1 AgSbF6 (10 ) DBU (10) CH2Cl2 rt 2h 83%
2 ZnCl2 (0.2) DBU (1.2) CH2Cl2 rt 16h n. a.
3 AgNO3 (0.2) DBU (1.2) CH2Cl2 rt 24h 71%
4 AgNO3 (0.2) f-BuOK (1.2) CH2Cl2 rt 1h 36%
5 AgNO3 (0.2) DBU (1.2) acetone rt 2h 91%
6 AgNO3 (0.2) DBU (0.4) acetone rt 10h 94%
7 AgNO3 (0.2) DBU (0.2) acetone rt 16h 91%
8 none f-BuOK (1.2) CH2Cl2 rt 5 min 24%
9 none DBU (2) THF 70oC 8h 55%
We then decided to explore the substrate scope of this reaction (Scheme
3.18). Secondary propargyl substrate 3.23 participated in the cyclization 
smoothly. However, only an inseparable 2:1 mixture of diastereomers was 
formed. Reaction of terminal substituted propargyl substrates such as 3.22 
resulted in an inseparable mixture of starting material and desired product. 
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Scheme 3.18 Cyclization o f propargyl vinyl ether: substrate scope
Two plausible mechanisms have been proposed for this reaction (Scheme
3.19). Direct 5-endo-dig cyclization of the transient anion 3.68 with the help of the 
silver salt seems feasible. Another possible pathway would involve a Wittig 
rearrangement followed by an intramolecular cyclization of the allenol 
intermediate 3.72. Because similar Wittig rearrangements normally require a 
stoichiometric amount of strong base, we believe the direct 5-endo-dig 
mechanism is more likely.9 To the best of our knowledge similar cyclizations of 
propargyl vinyl ethers have never been reported. This mechanism could also 
explain the incomplete cyclization of substrate 3.22 as the bulky phenyl group 
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Scheme 3.19 Two plausible mechanism for propargyl vinyl ether cyclization
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3.3.3 Synthesis of oxetanes and tetrahydrofurans
We have successfully demonstrated that the intramolecular cyclization of 
propargyl vinyl ethers give dihydrofurans. An alternative cyclization strategy is 
employing halide substrates such as 3.26 and 3.27 in an Sn2 fashion. We were 
pleased to find that treatment of 3.26 with DBU gave 3.74 in the absence of a 
silver catalyst (Scheme 3.20). This result was quite unexpected, because we 
initially speculated that the seemingly more stable pyran 3.75 would be the 
preferred product. Bromide 3.27 was then exposed to the same reaction to give 
tetrahydrofuran 3.76 in good yield (Scheme 3.21). It’s worth noting that furan 






Scheme 3.20 Oxetane formation via 4-exo-tert cyclization
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Scheme 3.21 Tetrahydrofuran formation via 5-exo-tert cyclization
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3.4 Efforts towards the synthesis of dysiherbaine analogs
3.4.1 Introduction
Natural products containing a tetrahydrofuran motif are abundant in nature. 
We became particularly interested in the dysiherbaine family of natural products 
and their analogs (Scheme 3.22). Dysiherbaine was first isolated in 1997 by the 
Sakai group from the marine Micronesian sponge Dysidea herbacea.10 The 
structure of dysiherbaine is quite intriguing: it contains a unique cis-fused 
hexahydrofuro[3,2,b] pyran backbone which is most likely derived from 
carbohydrate with a pedant amino acid (glutamate). In addition to its structure, 
neuropharmacological studies also revealed that this compound is a highly 
selective agonist towards the kainate (KA) subclass of ionotropic glutamate 
receptors.11 More detailed experiments indicated that dysiherbaine and its 
analogs preferred to bind kainate subtype GluK1 and to some extent GluK2. It 
has been shown that antagonists of GluK1 are effective towards diseases such 
as epilepsy and neurodegeneration.11 Neodysiherbaine showed a similar 
neurological profile but with a decreased binding affinity.12
dysiherbaine neodysiherbaine
Scheme 3.22 Dysiherbaine family natural products
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Several total syntheses of dysiherbaine have been accomplished. The first 
total synthesis of dysiherbaine was completed by the Snider group in 2000 
(Scheme 3.23).13 Starting from xylose derivative 3.79, the C8-C9 stereochemistry 
was secured by reacting epoxide 3.80 with methyl isocyanate. The 
tetrahydrofuran ring in 3.82 was formed by an Sn2 displacement of the mesylate 
in 3.81. While the alkylation of 3.82 with allyl bromide provided the desired 
stereochemistry at the C4 position, installation of the amino acid moiety gave 
only a 1:1 mixture of diastereomers of 3.84. Global deprotection provided the 
natural product from 3.79 in 17 steps.
The Hatakeyama group applied a compeletely different strategy in their total 
synthesis (Scheme 3.24).14 Starting from an achiral linear material 3.85, the 
absolute stereochemistry of C7 to C9 was introduced with a series of enantio- 
and diastereoselective transformations. The pyran ring in 3.87 was formed by an 
intramolecular Michael addition. Vinyl triflate 3.88 was then synthesized and 
coupled with enantioenriched zinc reagent 3.89 to form 3.90. The tetrahydrofuran 
ring was formed by a base promoted ring opening reaction of epoxide. Overall 
dysiherbaine was synthesized from 3.85 in 24 steps.
Chamberlin’s synthesis of dysiherbaine started with D-mannose derivative 
3.92. The coupling of glutamic acid 3.94 with triflate 3.93 produced the requisite 
pyran 3.95 (Scheme 3.25).15 The tetrahydrofuran ring was generated using a 
Fleet ring contraction reaction. The C8 methylamino group was installed at a late 
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Scheme 3.23 Snider's total synthesis of Dysiherbaine
99
1. BCI3, CH2CI2, -60°C
2. TBSCI, im idazole, DMF, rt




5. HF 47%, CH3CN, 70°C, 
then NaHC03






2. TESCI. im idazole. DMF. rt
3. MeMgBr, THF, 0°C









H N ' 2






(65% over 4 steps)
M e02C TESO,, A  <P
M e02C




1. 1M HCI, THF
2. m-CPBA, CH2CI2 (1:1 dr)
3. PPTS, acetone
4. NaOMe, MeOH
(20% over 4 steps)
M o
1.TPAP, NMO,CH2CI2
2.41%  NaOH aq., re f lu x ^  „  .. . . 
 -— -1-2----------►  Dysiherbaine
M e02C -.N^ " ' C° 2Me (76% over 2 s tePs)
H
3.91
Scheme 3.24 Hatakeyama's total synthesis of Dysiherbaine
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Scheme 3.25 Chamberlin's total synthesis of Dysiherbaine
3.4.2 Synthesis of dysiherbaine analogs 
Because of their notable neuro-activity, analogs of dysiherbaine have been 
synthesized in order to understand their structure-activity relationship (SAR) with 
glutamate receptors.16 Modifications at different positions on the dysiherbaine 
skeleton have been accomplished (Scheme 3.26). Interestingly, dysiherbaine 
analog MSVIII-19 without the C8 or C9 substitution was identified as the first 
known antagonist for GluK1.17 The C9 hydroxy group is important for binding with 
GluK1, because either loss of the C9 substituent or epimerization of it as in 
compound 3.99 and 3.100 resulted in greatly decreased binding affinity.18 The C8 
substitution affects the binding less dramatically as compound 3.101 maintained 
similar binding affinity as neodysiherbaine. The C4 epimer of neodysiherbaine 
3.102 lost its affinity significantly; interestingly, bis-C2, C4 epimer 3.103 restored 
the binding affinity and was an antagonist against GluK1.19
a-Amino phosphonic acids can be structural mimics of a-amino acids and 
have shown promising applications in medicinal chemistry.20 We envisioned that 
the phosphonic acid analog 3.104 of MSVIII-19 which has never been reported 
before can be accessible from our O-H insertion-cyclization approach, as shown 
in Scheme 3.27. The target molecule would be derived from phosphonate 3.105, 
which would be formed by an intramolecular cyclization of tosylate 3.106. At the 
outset we were not sure about the stereochemistry of the C4 carbon after the 
cyclization but we hoped that both C4 diastereomers could bring us useful 
information for the SAR study. The tosylate would be synthesized from an O-H 
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Scheme 3.26 Analogs o f Dysiherbaine
Compound 3.107 could be realized from commercially available galactose 
derivative 3.108.
With the aforementioned retrosynthetic analysis in mind, we set out to 
synthesize alcohol 3.107 first (Scheme 3.28). Treating compound 3.108 with 
Ferrier rearrangement condition readily provided alkene 3.109. Subsequent 
hydrogenation and deprotection resulted in diol 3.110. The primary alcohol was 
selectively protected as the corresponding TBS ether to give the alcohol 
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Scheme 3.27 Retrosynthetic analysis of phosphonic acid analog
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Scheme 3.28 Synthesis o f alcohol precursor
To our delight, the key O-H insertion reaction between diazo 3.4 and alcohol
3.107 went smoothly and gave the desired insertion product 3.111 in 68% yield 
(Scheme 3.29). Removal of the TBS group provided the primary alcohol in 74% 
yield, which upon treating with TsCl and DMAP gave the corresponding tosylate
3.106 in 89% yield. The stage now was set for the cyclization. When treating the 




°  —  MeOzC.
Me02C
n^OEt HO, Meu2u vY^ sv /
V ^ ^ O E t  + 1 ^ 1  Rh2(OAc)4 (1 mo.%) T
B2 + TBS0 ^ A 0 ^  CH2CI2j rt " * | ^ |




11 .OEt O ^  
Me02C. ^ P '  ______  "^O Et
0E t 2 ^OFt
PPTS, EtOH ^  ^  ____ TsCI, NEt3, DMAP 0Et
(74%) HO . C j  CH2C'2’ 11





P  Hacetone, rt \
EtO OEt
(85%) 3.113
Scheme 3.29 Synthesis of phosphonate analog
85% yield. NOE experiments revealed that the stereochemistry of the C-4 carbon 
was actually opposite to the the C-4 stereochemistry in the natural product 
dysiherbaine.
We are currently working on the rationalization of the stereo outcome of the 
cyclization. Because the 2,4-epi-NeoDH 3.103 showed strong binding affinity 
while 2-epi-NeoDH 3.102 only weakly binds to GluK1, in the next stage we plan 
to aim for the 2,4-epimer of the phosphonic acid analog 3.114 (Scheme 3.30). 
Since the C-9 substitution is proved to be important for binding affinity, we also 





















Scheme 3.30 Future work
3.5 Conclusion
Diazo vinyl phosphonate 3.4 participated in stereoselective X-H insertion 
reactions to give enol ethers, enamines and vinyl sulfides. Subsequent 
cyclization of O-H insertion products provided a rapid access to dihydrofurans, 
oxetanes and tetrahydrofurans. Notably, the O-H insertion/cyclization strategy 
was applied to the synthesis of dysiherbaine analogs.
Future work will focus on exploring new reactivity of this novel diazo vinyl 
phosphonate. Currently, the possibility of conjugating the phosphonate onto iron 
nanoparticles is under investigation in our group. The synthesis of other 
phosphonate analogs of dysiherbaine is another direction we will pursue.
3.6 Experimental
NMR spectra were recorded on a Varian Unity-300, Varian Inova-400 or a 
Varian VXR-500 spectrometer. Chemical shifts were reported in 5, parts per
106
million (ppm), relative to chloroform (7.25) or dichloromethane (5.29) as internal 
standards. Coupling constants, J, were reported in Hertz (Hz) and refer to 
apparent peak multiplicities and not true coupling constants. Mass spectra were 
recorded at the Mass Spectrometry Facility at the Department of Chemistry of the 
University of Utah at Salt Lake City on a Finnigan MAT 95 mass spectrometer. IR 
spectra were recorded on a Bruker Tensor 27 FT-IR spectrometer. Solvents were 
purified according to the guidelines in Purification of Common Laboratory 
Chemicals (Armarego. W. L. F. and Chai, C. L. L., Oxford, 2009). Spectroscopic 
grade CH3CN was stored over activated 4A molecular sieves and used without 
additional purification. All other reagents were used without purification. Unless 
otherwise stated, all reactions were run under an atmosphere of dried nitrogen in 
flame-dried glassware. Concentration refers to removal of solvent under reduced 
pressure (house vacuum at ca. 20 mmHg).
Methyl-E-2-diazo-4-(diethoxyphosphoryl)but-3-enoate (3.4). To a solution of
3.1 (0.236 g, 1.0 mmol) and tosyl azide (0.236 g, 1.2 mmol) in THF (8 mL) at 
0 °C was added DBU (0.18 mL, 1.2 mmol) dropwise. The resulting mixture was 
warmed to rt slowly and allowed to stir for 8 h. Concentration and flash 
chromatography (1:2 hexanes:ethyl acetate) provided 0.206 g of diazo vinyl 
phosphonate 3.4 (80%) as a pale yellow oil.
3.4: 1H NMR (500 MHz, CDCb) 5 7.08 (dd, J = 22.5, 17.6 Hz, 1H), 5.50 (dd, J =




NMR (125 MHz, CDCI3) 5 163.7, 134.6 (d, J = 11.5 Hz), 107.1 (d, J = 197.6 Hz),
62.1 (d, J = 7.9 Hz), 52.7, 16.6 (d, J = 7.9 Hz); IR (neat) 2983, 2916, 2114, 1709, 
1602, 1439, 1337, 1244, 1217, 1051, 1025, 962 cm-1; LRMS m/z calcd for 
C9H16N2O5P [M+H]+ 263.1, found 263.2.
Methyl 3-(diethoxyphosphoryl)-7H-pyrazole-5-carboxylate (3.6). A solution of 
diazo 3.4 29 mg (0.11 mmol) in toluene (3 ml) was heated at 80 °C for 12 h. 
Concentration and flash chromatography (1:5 hexanes/ethyl acetate) gave 21 mg 
of 3.6 (71%) as a colorless oil.
3.6: 1H NMR (300 MHz, CDCls) 5 7.15 (d, J = 2.2 Hz, 1H), 4.21 - 4.02 (m, 4H), 
3.87 (s, 3H), 1.26 (t, J = 7.0 Hz, 6H); 13C NMR (75 MHz, CDCb) 5 162.0, 142.7,
134.5 (d, J = 228.1 Hz), 114.7 (d, J = 19.1 Hz), 63.6 (d, J = 5.5 Hz), 52.4, 16.3 (d, 
J = 6.6 Hz); IR (neat) 3128, 3053, 2983, 1732, 1457, 1365, 1225, 1174, 1051, 
1017, 977 cm-1; LRMS m/z calcd for C9H16N2O5P [M+H]+ 263.1, found 363.1
Representative procedure for O-H, N-H and S-H insertion reactions of diazo vinyl 
phosphonate 3.4:
The generation of butyl enol ether 3.17: To a solution of 3.4 (0.026 g, 0.099 






Rh2(OAc)4 (0.9 mg, 0.002 mmol) in a single portion. The resulting green mixture 
was allowed to stir at rt for 4 h. Concentration and flash chromatography (1:1 
hexanes:ethyl acetate, SiO2 was neutralized with 1% NEt3) provided 25 mg of 
enol ether 3/17 (82%) as a colorless oil.
3.17: 1H NMR (500 MHz, CDCb) 5 6.18 (dt, J = 7.5, 7.5 Hz, 1H), 4.14 - 4.03 (m, 
4H), 3.81 (t, J = 6.9 Hz, 2H), 3.74 (s, 3H), 2.77 (dd, J = 22.4, 7.8 Hz, 2H); 1.64 
(pentet, J = 6.8 Hz, 2H), 1.41 (sextet, J = 7.4 Hz, 2H), 1.29 (t, J = 6.8 Hz, 6H), 
0.92 (t, J = 7.3 Hz, 3H); 13C NMR (125 MHz, CDCls) 5 163.9 (d, J = 3.1 Hz),
147.6 (d, J = 13.7 Hz), 117.1 (d, J = 10.6 Hz), 72.6 (d, J = 2.3 Hz), 62.3 (d, J =
6.1 Hz), 52.2, 32.2, 24.5 (d, J = 140.4 Hz), 19.3, 16.6 (d, J = 6.1 Hz), 14.0; IR 
(neat) 2958, 1727, 1650, 1437, 1252, 1164, 1107, 1024, 963 cm-1; LRMS m/z 
calcd for C13H26O6P 309.1 [M+H]+, found 309.3.
Methyl-Z-4-(diethoxyphosphoryl)-2-isopropoxybut-2-enoate (3.18). Enol 
ether was prepared according to the procedure given for the formation of 3.17 
using 0.025 g (0.095 mmol) of 3.4, 0.015 mL (0.19 mmol) of isopropyl alcohol 
and 0.8 mg (0.002 mmol) of Rh2(OAc)4 to give 23 mg of 3.18 (82%) as colorless 
oil after flash chromatography (1:1 hexane/ ethyl acetate, SiO2 was neutralized 
with 1% NEt3).
3.18: 1H NMR (500 MHz, CDCb) 5 6.20 (dt, J = 7.8, 7.8 Hz, 1H), 4.28 (septet, J =
5.9 Hz, 1H), 4.14 - 4.04 (m, 4H), 3.74 (s, 3H), 2.78 (dd, J = 22.5, 8.3 Hz, 2H),
3.18
1.29 (t, J = 7.3 Hz, 6H), 1.21 (d, J = 6.3 Hz, 6H); 13C NMR (125 MHz, CDCb) 5
164.1 (d, J = 2.3 Hz), 146.2 (d, J = 14.6 Hz), 117.4 (d, J = 10.7 Hz), 74.2 (d, J =
2.3 Hz), 62.3 (d, J = 6.1 Hz), 52.2, 24.6 (d, J = 141.2 Hz), 22.6, 16.6 (d, J = 6.1 
Hz); IR (neat) 3020, 2981, 1724, 1647, 1437, 1265, 1249, 1193, 1024, 964 cm-1; 
LRMS m/z calcd for C12H24O6P 295.2 [M+H]+, found 295.3.
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3.19
Methyl-Z-2-(allyloxy)-4-(diethoxyphosphoryl)but-2-enoate (3.19). Allyl enol 
ether 3.19 was prepared according to the procedure given for the formation of
3.17 using 0.026 g (0.099 mmol) of 3.4, 0.014 mL (0.20 mmol) of prop-2-en-1-ol 
and 0.9 mg (0.002 mmol) of Rh2(OAc)4 to give 24 mg of 3.19 (83%) as colorless 
oil after flash chromatography (1:1 hexanes/ethyl acetate, SiO2 was neutralized 
with 1% NEt3).
3.19: 1H NMR (500 MHz, CDCb) 5 6.24 (dt, J = 7.8, 7.8 Hz, 1H), 5.96 (ddt, J =
17.1, 10.8, 5.8 Hz, 1H), 5.32-5.29 (m, 1H), 5.20 (dd, J = 11.7, 1.0 Hz, 1H), 4.38 
(d, J = 5.9 Hz, 2H), 4.14 - 4.04 (m, 4H), 3.76 (s, 3H), 2.78 (dd, J = 22.4, 7.8 Hz, 
2H), 1.30 (t, J = 6.8 Hz, 6H); 13C NMR (125 MHz, CDCb) 5 163.7 (d, J = 3.1 Hz),
147.1 (d, J = 14.5 Hz), 133.6, 118.6, 117.9 (d, J = 10.7 Hz), 73.4 (d, J = 3.0 Hz),
62.3 (d, J = 6.9 Hz), 52.3, 24.6 (d, J = 141.2 Hz), 16.6 (d, J = 6.1 Hz); IR (neat) 
2984, 1727, 1651, 1438, 1253, 1046, 1024, 964 cm-1; LRMS m/z calcd for 
C12H22O6P 293.1 [M+H]+, found 293.3
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Homoallyl enol ether 3.20 was prepared according to the procedure given for the 
formation of 3.17 using 0.025 g (0.095 mmol) of 3.4, 0.016 mL (0.19 mmol) of 
but-3-en-1-ol and 0.8 mg (0.002 mmol) of Rh2(OAc)4 to give 24 mg of 3.20 (82%) 
as a colorless oil after flash chromatography (1:1 hexane:ethyl acetate, SiO2 was 
neutralized with 1% NEt3).
3.20: 1H NMR (500 MHz, CDCb) 5 6.20 (dt, J = 6.8, 6.8 Hz, 1H), 5.83 (ddt, J =
17.1, 10.3, 6.3 Hz, 1H), 5.14-5.10 (m, 1H), 5.08-5.04 (m, 1H), 4.14 - 4.04 (m, 
4H), 3.89 (t, J = 6.3 Hz, 2H), 3.75 (s, 3H), 2.78 (dd, J = 22.9, 8.3 Hz, 2H), 2.44­
2.40 (m, 2H), 1.30 (t, J = 6.9 Hz, 6H); 13C NMR (125 MHz, CDCb) 5 163.8 (d, J =
3.0 Hz), 147.4 (d, J = 13.8 Hz), 134.7, 117.6 (d, J = 10.6 Hz), 117.3, 71.9 (d, J =
3.1 Hz), 62.3 (d, J = 6.1 Hz), 52.2, 34.5, 24.6 (d, J = 140.4 Hz), 16.6 (d, J = 6.1 
Hz); IR (neat) 2981, 1727, 1653, 1437, 136, 1253, 1165, 1025, 964 cm-1; LRMS 
m/z calcd for C13H24O6P 307.1 [M+H]+, found 307.3.
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3.21
Methyl-Z-4-(diethoxyphosphoryl)-2-(prop-2-yn-1 -yloxy)but-2-enoate 3.21.
Propargyl enol ether 3.21 was prepared according to the procedure given for the 




prop-2-yne-1-ol and 0.8 mg (0.002 mmol) of Rh2(OAc)4 (0.01 eq) to give 43 mg of 
3.21 (74%) as a colorless oil after flash chromatography (1:1 hexane/ ethyl 
acetate, SiO2 was neutralized with 1% NEt3).
3.21: 1H NMR (500 MHz, CDCls) 5 6.37 (dt, J = 7.9, 7.9 Hz, 1H), 4.62 (d, J = 2.5 
Hz, 2H), 4.14 - 4.04 (m, 4H), 3.76 (s, 3H), 2.87 (dd, J = 22.5, 7.9 Hz, 2H), 2.46 (t, 
J = 2.4 Hz, 1H), 1.30 (t, J = 6.8 Hz, 6H); 13C NMR (125 MHz, CDCb) 5 163.2 (d, 
J = 3.1 Hz), 145.6 (d, J = 14.5 Hz), 120.0 (d, J = 10.7 Hz), 78.7, 76.1, 62.4 (d, J =
6.1 Hz), 59.5 (d, J = 3.0 Hz), 52.4, 24.9 (d, J = 140.4 Hz), 16.6 (d, J = 6.1 Hz); IR 
(neat) 3204, 2983, 1724, 1652, 1438, 1324, 1250, 1106, 1019, 962 cm-1; LRMS 
m/z calcd for C12H20O6P 291.1 [M+H]+, found 291.2.
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(3.22). Propargyl enol ether 3.22 was prepared according to the general 
procedure given for the formation of 3.17 using 52 mg (0.20 mmol) of 3.4, 49 ^L 
(0.40 mmol) of 3-phenyl-2- propyn-1-ol and 0.9 mg (0.002 mmol) of Rh2(OAc)4 to 
give 58 mg of 3.22 (79%) as a colorless oil after flash chromatography (1:1 
hexane/ ethyl acetate, SiO2 was neutralized with 1% NEt3).
3.22: 1H NMR (500 MHz, CDCb) 5 7.40-7.38 (m, 2H), 7.32 - 7.27 (m, 3H), 6.41 
(dt, J = 7.8, 7.8 Hz, 1H), 4.85 (s, 2H), 4.14 - 4.04 (m, 4H), 3.79 (s, 3H), 2.93 (dd, 
J = 22.5, 7.8 Hz, 2H), 1.28 (t, J = 6.8 Hz, 6H); 13C NMR (125 MHz, CDCb) 5
163.5 (d, J = 2.3 Hz), 145.9 (d, J = 13.7 Hz), 131.9, 128.9, 128.6, 122.4, 120.0
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(d, J = 10.7 Hz), 87.8, 84.0, 62.4 (d, J = 6.2 Hz), 60.4 (d, J = 3.8 Hz), 52.4, 24.9 
(d, J =140.4 Hz), 16.6 (d, J = 6.1 Hz); IR (neat) 2981, 1724, 1651, 1442, 1251, 
1019, 963 cm-1; LRMS m/z calcd for C18H24O6P 367.1 [M+H]+, found 367.3.
Methyl-Z-2-(but-3-yn-2-yloxy)-4-(diethoxyphosphoryl)but-2-enoate (3.23).
Propargyl enol ether 3.23 was prepared according to the general procedure 
given for the formation of 3.17 using 41 mg (0.16 mmol) of 3.4, 25 ^L (0.31 
mmol) of 3-butyn-2-ol and 0.7 mg of Rh2(OAc)4 (0.002 mmol) to give 33 mg of 
3.23 (69%) as a colorless oil after flash chromatography (1:1 hexane/ ethyl 
acetate. SiO2 was neutralized with 1% NEt3).
3.23: 1H NMR (500 MHz, CDCls) 5 6.36 (dt, J = 9.2, 6.9 Hz, 1H), 4.94 - 4.90 (m, 
1H), 4.14 - 4.04 (m, 4H), 3.76 (s, 3H), 3.08 (ddd, J = 20.5, 15.1, 9.3 Hz, 1H), 2.70 
(ddd, J = 23.9, 15.6, 6.8 Hz, 1H), 2.42 (d, J = 2.0 Hz, 1H), 1.55 (d, J = 6.2 Hz, 
3H), 1.30 (t, J = 6.7 Hz, 6H); 13C NMR (125 MHz, CDCb) 5 163.6 (d, J = 2.3 Hz),
145.4 (d, J = 14.5 Hz), 120.0 (d, J = 10.7 Hz), 82.8, 74.4, 67.0 (d, J = 2.3 Hz),
62.3 (d, J = 2.3 Hz), 62.3 (d, J = 2.2 Hz), 52.3, 25.0 (d, J = 140.3 Hz), 22.3, 16.6 
(d, J = 2.2 Hz), 16.6 (d, J = 2.2 Hz); IR (neat) 3207, 2985, 1725, 1651, 1252,
1103, 1025, 964 cm-1; LRMS m/z calcd for C13H22O6P 305.1 [M+H]+, found 305.3.
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Propargyl enol ether 3.24 was prepared according to the general procedure 
given for the formation of 3.17 using 41 mg (0.16 mmol) of 3.4, 29 ^L (0.31 
mmol) of 2-pentyn-1-ol and 0.7 mg (0.002 mmol) of Rh2(OAc)4 to give 35 mg 
(70%) of 3.24 as a colorless oil after flash chromatography (1:1 hexane/ ethyl 
acetate, SiO2 was neutralized with 1% NEt3).
3.24: 1H NMR (500 MHz, CDCb) 5 6.34 (dt, J = 8.3, 8.3 Hz, 1H), 4.56 (t, J = 2.5 
Hz, 2H), 4.14 - 4.04 (m, 4H), 3.75 (s, 3H), 2.86 (dd, J = 22.5, 7.8 Hz, 2H), 2.18 
(qt, J = 7.3, 2.4 Hz, 2H), 1.30 (t, J = 7.3 Hz, 6H), 1.09 (t, J = 7.4 Hz, 3H); 13C 
NMR (125 MHz, CDCb) 5 163.5 (d, J = 3.1 Hz), 146.0 (d, J = 14.6 Hz), 119.6 (d, 
J = 10.7 Hz), 90.1, 74.4, 62.3 (d, J = 6.1 Hz), 60.3 (d, J = 3.1 Hz), 52.3, 24.8 (d, J 
= 140.3 Hz), 16.6 (d, J = 6.1 Hz), 13.8, 12.6; IR (neat) 2981, 1725, 1651, 1252,




Methyl-Z-4-(diethoxyphosphoryl)-2-phenoxybut-2-enoate (3.25). Phenyl enol 
ether 3.25 was prepared according to the general procedure given for the 
formation of 3.17 using 25 mg (0.095 mmol) of 3.4, 18 mg (0.19 mmol) phenol 
and 0.8 mg (0.002 mmol) of Rh2(OAc)4 to give 17.4 mg of 3.25 (56%) as a 
colorless oil after flash chromatography (1:1 hexane/ ethyl acetate, SiO2 was 
neutralized with 1% NEt3).
3.25: 1H NMR (500 MHz, CDCb) 5 7.28 (t, J = 7.3 Hz, 2H), 7.03 (dt, J = 7.3, 1.0 
Hz, 1H), 6.91 (dd, J = 7.8, 0.9 Hz, 2H), 6.61 (dt, J = 7.9, 7.9 Hz, 1H), 4.09 (dq, J
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= 7.0, 7.0 Hz, 4H), 3.71 (s, 3H), 2.80 (dd, J = 22.5, 7.9 Hz, 2H), 1.30 (t, J = 7.3 
Hz, 6H); 13C NMR (125 MHz, CDCb) 5 163.0 (d, J = 2.3 Hz), 157.1 (d, J = 2.3 
Hz), 143.4, (d, J = 14.5 Hz), 129.8, 122.9, 121.2 (d, J = 9.9 Hz), 115.5, 62.4 (d, J 
= 6.2 Hz), 52.6, 24.8 (d, J = 140.4 Hz), 16.6 (d, J = 6.1 Hz); IR (neat) 2983, 1734, 
1661, 1491, 1256, 1214, 1024, 967 cm-1; LRMS m/z calcd for C15H22O6P 329.1 
[M+H]+, found 329.3.
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3.26
Methyl-Z-4-(diethoxyphosphoryl)-2-(2-iodoethoxy)but-2-enoate (3.26). 2-
Iodoethyl enol ether 3.26 was prepared according to the general procedure given 
for the formation of 3.17 using 33 mg (0.13 mmol) of 3.4, 20. ^L (0.25 mmol) of 2- 
iodo-1-ethanol and 1 mg (0.002 mmol) of Rh2(OAc)4 to give 40. mg of 3.26 (78%) 
as a colorless oil after flash chromatography (1:1 hexane/ ethyl acetate, SiO2 
was neutralized with 1% NEt3).
3.26: 1H NMR (300 MHz, CDCb) 5 6.23 (dt, J = 8.2, 6.7 Hz, 1H), 4.13 - 4.03 (m, 
6H), 3.73 (s, 3H), 3.32 (t, J = 6.7 Hz, 2H), 2.84 (dd, J = 22.8, 8.2 Hz, 2H), 1.28 (t, 
J = 7.1 Hz, 6H); 13C NMR (125 MHz, CDCb) 5 163.4, 146.5 (d, J = 14.1 Hz),
118.5 (d, J = 11.1 Hz), 72.6 (d, J = 3.1 Hz), 62.4 (d, J = 6.6 Hz), 52.4, 24.9 (d, J =
140.0 Hz), 16.6 (d, J = 6.0 Hz), 2.4; IR (neat) 2981, 1726, 1651, 1437, 1330, 
1253, 1108, 1045, 1024, 964 cm-1; LRMS m/z calcd for C11H21IO6P 407.0 [M+H]+, 
found 407.0.
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3.27
Methyl-Z-2-(3-bromopropoxy)-4-(diethoxyphosphoryl)but-2-enoate (3.27). 3-
Bromopropyl enol ether 3.27 was prepared according to the general procedure 
given for the formation of 3.17 using 41 mg (0.16 mmol) of 3.4, 28 ^L (0.31 
mmol) of 3-bromo-1-propanol and 0.7 mg (0.002 mmol) of Rh2(OAc)4 to give 43 
mg of 3.27 (74%) as a colorless oil after flash chromatography (1:1 hexane/ ethyl 
acetate, SiO2 was neutralized with 1% NEt3).
3.27: 1H NMR (500 MHz, CDCb) 5 6.25 (dt, J = 7.8, 7.8 Hz, 1H), 4.14 - 4.06 (m, 
4H), 3.96 (t, J = 5.9 Hz, 2H), 3.77 (s, 3H), 3.57 (t, J = 6.3 Hz, 2H), 2.78 (dd, J =
23.0, 8.3 Hz, 2H), 2.22 (p, J = 6.4 Hz, 2H), 1.31 (t, J = 7.3 Hz, 6H); 13C NMR (125 
MHz, CDCls) 5 163.6 (d, J = 3.0 Hz), 147.2 (d, J = 14.4 Hz), 117.8 (d, J = 10.7 
Hz), 70.1 (d, J = 3.1 Hz), 62.4 (d, J = 6.1 Hz), 52.3, 33.2, 30.1, 24.6 (d, J = 141.2 
Hz), 16.6 (d, J = 6.1 Hz); IR (neat) 2981, 1726, 1651, 1438, 1253, 1112, 1023, 
964 cm-1; LRMS m/z calcd for C12H23BrO6P [M+H]+ 373.0 and 375.0, found 373.1 
and 375.0.
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enoate (3.31). N-Boc enamine 3.31 was prepared according to the general 
procedure given for the formation of 3.17 using 25 mg (0.095 mmol) of 3.4, 22
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mg (0.19 mmol) of tert-butyl carbamate and 0.8 mg (0.002 mmol) of Rh2(OAc)4 to 
give 26 mg of 3.31 (78%) as a colorless oil after flash chromatography (1:1 
hexane/ethyl acetate, SiO2 was neutralized with 1% NEt3).
3.31: 1H NMR (300 MHz, CDCb) 5 6.76 (broad s, 1H), 6.33 (dt, J = 7.5, 7.5 Hz, 
1H), 4.17-4.04 (m, 4H), 3.76 (s, 3H), 2.77 (dd, J = 22.5, 8.1 Hz, 2H), 1.43 (s, 9H),
1.30 (t, J = 7.1 Hz, 6H); 13C NMR (125 MHz, CDCb) 5 165.0, 153.3 (d, J = 1.6 
Hz), 130.8, 121.9, 81.0, 62.6 (d, J = 6.9 Hz), 52.6, 28.3, 26.6 (d, J = 138.9 Hz),
16.6 (d, J = 5.4 Hz); IR (neat) 3231, 2980, 1721, 1656, 1497, 1367, 1247, 1164, 









enoate (3.32). N-Tosyl enamine 3.32 was prepared according to the general 
procedure given for the formation of 3.17 using 42 mg (0.16 mmol) of 3.4, 41 mg 
(0.32 mmol) of toluenesulfonylamide and 0.7 mg (0.002 mmol) of Rh2(OAc)4 to 
give 32 mg of 3.32 (49%) as colorless oil after flash chromatography (1:1 
hexane/ ethyl acetate, SiO2 was neutralized with 1% NEt3).
3.32: 1H NMR (300 MHz, CDCb) 5 7.70 (d, J = 8.4 Hz, 2H), 7.28 (d, J = 7.9 Hz, 
2H), 6.84 (dt, J = 8.1, 8.1 Hz, 1H), 6.68 (broad s, 1H), 4.18 - 4.06 (m, 4H), 3.50 
(s, 3H), 3.06 (dd, J = 22.1, 7.8 Hz, 2H), 2.42 (s, 3H), 1.33 (t, J = 7.0 Hz, 6H); 13C 
NMR (125 MHz, CDCb) 5 164.1 (d, J = 2.3 Hz), 144.3, 136.5, 131.8 (d, J = 9.2 
Hz), 129.7, 128.7 (d, J = 14.5 Hz), 127.8, 127.7 62.6 (d, J = 6.9 Hz), 52.7, 27.1
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(d, J = 138.1 Hz), 21.8, 16.6 (d, J = 5.3 Hz); IR (neat) 2985, 1727, 1654, 1438, 






Methyl-Z-2-acetamido-4-(diethoxyphosphoryl)but-2-enoate (3.33). To a
solution of diazo vinylphosphonate 3.4 (26 mg, 0.099 mmol) and acetamide (12 
mg, 0.20 mmol) in toluene (2 mL) at rt was added Rh2(OAc)4 (0.9 mg, 0.002 
mmol). The reaction mixture was heated to 60 °C and stirred for 2h. After cooling 
to rt the reaction mixture was concentrated. Flash chromatography (30:1 
CH2Cl2/MeOH) gave 16.6 mg of 3.33 (58%) as a colorless oil.
3.33: 1H NMR (300 MHz, CDCb) 5 8.20 (br, 1H), 6.38 (dt, J = 8.1, 8.1 Hz, 1H), 
4.12 - 4.02 (m, 4H), 3.74 (s, 3H), 2.69 (dd, J = 22.7, 7.9 Hz, 2H), 2.08 (s, 3H), 
1.29 (t, J = 7.0 Hz, 6H); 13C NMR (75 MHz, CDCb) 5 169.3, 164.6 (d, J = 3.0 Hz),
131.2 (d, J = 13.1 Hz), 112.9 (d, J = 11.6 Hz), 62.8 (d, J = 7.1 Hz), 52.7, 26.6 (d, 
J = 139.0 Hz), 23.3, 16.6 (d, J = 6.1 Hz) IR (neat) 3250, 2986, 1729, 1693, 1517, 
1438, 1370, 1246, 1024, 969 cm-1; LRMS m/z calcd for C11H21NO6P [M+H]+








Phenyl enamine 3.34 was prepared according to the general procedure given for 
the formation of 3.17 using 25 mg (0.095 mmol) of 3.4, 18 ^L (0.19 mmol) of 
aniline and 0.8 mg (0.002 mmol) of Rh2(OAc)4 to give 22 mg of 3.34 (71%) as a 
colorless oil after flash chromatography (1:1 hexane/ ethyl acetate, SiO2 was 
neutralized with 1% NEt3).
3.34: 1H NMR (300 MHz, CDCb) 5 7.22 - 7.15 (m, 2H), 6.85 - 6.80 (m 1H), 6.65 - 
6.61 (m, 2H), 6.36-6.28 (m, 2H), 4.15 - 4.05 (m, 4H), 3.74 (s, 3H), 2.66 (dd, J =
22.8, 8.1 Hz, 2H), 1.31 (t, J = 7.1 Hz, 3H), 1.31 (dt, J = 7.1, 0.4 Hz, 6H); 13C NMR 
(125 MHz, CDCb) 5 166.0 (d, J = 2.3 Hz), 143.9, 133.6 (d, J = 12.9 Hz), 129.3,
120.2, 118.1 (d, J = 12.2 Hz), 115.8, 62.6 (d, J = 6.8 Hz), 52.6, 26.9 (d, J = 140.4 
Hz), 16.6 (d, J = 6.1 Hz); IR (neat) 3291, 2984, 1731, 1639, 1602, 1491, 1438, 
1245, 1024, 966 cm-1; LRMS m/z calcd for C15H3NO5P 328.1 [M+H]+, found
328.1.
tert-butyl ((2E,4Z)-4-(2-(diethoxyphosphoryl)ethylidene)-5-oxoimidazolidin- 
2- ylidene)carbamate (3.35). To a solution of 3.4 (69 mg, 0.26 mmol), N-Boc 
guanidine (84 mg, 0.53 mmol) and approximately 0.5 g 4A molecular sieves in 
CH2Cl2 (3 mL) at rt was added Rh2(esp)2 (4.0 mg, 0.0053 mmol) in a single 
portion. The resulting yellow mixture was allowed to stir at rt for 1 day. 





MeOH:CH2Cl2 with 0.1% ammonium hydroxide) provided 55 mg of cyclic 
guanidine 3.35 (57%) as a colorless oil. Guanidine 3.35 was characterized as its 
hydrogenated derivative 3.36.
ylidenecarbamate (3.36). To a solution of 3.36 (54 mg, 0.15 mmol) in ethyl 
acetate was added 10% Pd/C (32 mg, 0.030 mmol) at rt. The resulting mixture 
was allowed to react at rt under 1 atm H2 atmosphere for 6 h. Filtrate through 
celite and concentrate. Flash chromatograpgy (1:20 MeOH:CH2Cl2 with 0.1% 
ammonium hydroxide) provided 46 mg of guanidine 3.36 (85%) as a colorless oil. 
3.36: 1H NMR (500 MHz, CDCls) 5 8.76 (broad s, 1H), 4.17 - 4.05 (m, 5H), 2.29 - 
2.19 (m, 1H), 2.05 - 1.88 (m, 2H), 1.85 - 1.74 (m, 1H), 1.53 (s, 9H), 1.32 (t, J =
7.3 Hz, 3H), 1.31 (t, J = 7.3 Hz, 3H); 13C NMR (125 MHz, CDCb) 5 183.7, 167.3,
155.2, 83.2, 62.1 (d, J = 6.9 Hz), 59.8, 28.2 (d, J = 2.3 Hz), 25.3, 22.0 (d, J =
141.5 Hz), 16.7 (d, J = 3.2 Hz), 16.6 (d, J = 2.2 Hz); IR (neat) 2924, 1735, 1671, 
1621, 1592, 1561, 1243, 1148, 1022, 959 cm-1; LRMS m/z calcd for C14H27N3O6P 









Thiophenyl ether 3.38 was prepared according to the general procedure given for 
the formation of 3.17 using 33 mg (0.13 mmol) of 3.4, 26 ^L (0.25 mmol) of 
thiophenol and 0.9 mg (0.002 mmol) of Rh2(OAc)4 to give 35.1 mg of 3.38 (81%) 
as a colorless oil after flash chromatography (1:1 hexane/ ethyl acetate, SiO2 
was neutralized with 1% NEt3).
3.38: 1H NMR (500 MHz, CDCb) 5 7.34 (dt, J = 7.8, 6.9 Hz, 1H), 7.26 - 7.21 (m, 
4H), 7.18 - 7.15 (m, 1H), 4.15 - 4.09 (m, 4H), 3.64 (s, 3H), 3.18 (dd, J = 23.5, 8.4 
Hz, 2H), 1.32 (t, J = 7.3 Hz, 6H); 13C NMR (125 MHz, CDCb) 5 165.3 (d, J = 3.1 
Hz), 141.6 (d, J = 11.4 Hz), 135.0 (d, J = 2.3 Hz), 130.8 (d, J = 14.5 Hz), 129.2,
128.8, 126.7, 62.6 (d, J = 6.9 Hz), 52.9 (d, J = 2.3 Hz), 30.1 (d, J = 138.1 Hz),
16.6 (d, J = 6.1 Hz); IR (neat) 2983, 1718, 1653, 1437, 1250, 1023, 966 cm-1; 
LRMS m/z calcd for C15H22O5PS 345.1 [M+H]+, found 345.3. 
o






(3.42). To a solution of N-Boc enamine 3.31 (25 mg, 0.071 mmol) in ethyl acetate 
(3 mL) at rt was added Pd/C (10%, 8.0 mg (0.0075 mmol)). The resulting mixture 
was subjected to H2 (1 atm). After 12 h the reaction mixture was filtered through 
celite. Concentration and flash chromatography (1:5 hexanes/ethyl acetate) gave 
25 mg of 3.42 (98%) as a colorless oil.
3.42: 1H NMR (300 MHz, CDCb) 5 5.10 (broad d, J = 8.1 Hz, 1H), 4.26 - 4.16 (m, 
1H), 4.03 - 3.91 (m, 4H), 3.63 (s, 3H), 2.15 - 1.94 (m, 2H), 1.88 - 1.59 (m, 2H),
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1.32 (s, 9H), 1.20 (t, J = 7.1 Hz, 6H); 13C NMR (125 MHz, CDCb) 5 172.6, 155.6,
80.3, 61.9 (d, J = 6.7 Hz), 53.7 (d, J = 17.7 Hz), 52.7, 28.5, 26.2 (d, J = 3.7 Hz),
22.0 (d, J = 143.4 Hz), 16.6 (d, J = 6.1 Hz); IR (neat) 3266, 2979, 1745, 1710, 
1526, 1447, 1392, 1366, 1244, 1216, 1164, 1051, 1024, 963 cm-1; LRMS m/z 
calcd for C14H29NO7P [M+H]+ 354.2, found 354.3.
Methyl 3-((diethoxyphosphoryl) methyl)-2-oxohex-5-enoate (3.56). A solution 
of 3.19 (58 mg, 0.20 mmol) in toluene was stirred at 80 °C for 16 h, cooled to rt 
and concentrated. Flash chromatography (1:1 hexanes:ethyl acetate) provided 
43 mg of ketoester 3.56 (74%) as a colorless oil.
3.56: 1H NMR (500 MHz, CDCb) 5 5.64 (ddt, J = 17.1, 9.8, 7.3 Hz, 1H), 5.07 (d, J 
= 9.7 Hz, 1H), 5.05 (d, J = 18.1 Hz, 1H), 4.09 - 3.97 (m, 4H), 3.85 (s, 3H), 3.76 - 
3.68 (m, 1H), 2.47 (ddd, J = 14.2, 6.3, 6.3 Hz, 1H), 2.31 - 2.18 (m, 2H), 1.91 
(ddd, J = 18.4, 15.6, 3.9 Hz, 1H), 1.26 (t, J = 7.3 Hz, 3H), 1.25 (t, J = 7.3 Hz, 3H); 
13C NMR (125 MHz, CDCb) 5 194.8 (d, J = 5.5 Hz), 161.1, 133.4, 119.1, 62.1 (d, 
J = 6.7 Hz), 61.9 (d, J = 6.1 Hz), 53.2, 41.4 (d, J = 3.7 Hz), 36.7 (d, J = 13.4 Hz),
26.2 (d, J = 142.2 Hz), 16.5 (d, J = 5.5 Hz), 16.4 (d, J = 6.1 Hz); IR (neat) 2982, 
1729, 1641, 1441, 1240, 1020, 959, 804 cm-1; LRMS m/z calcd for C12H22O6P 







(3.61). To a solution of enol ether 3.21 (41.7 mg, 0.140 mmol) in acetone (2 mL) 
in the dark was added AgNO3 (4.9 mg, 0.0029 mmol) and DBU (26 ^L, 0.17 
mmol). The resulting reaction mixture was allowed to stir at rt for 3 h and was 
then concentrated. Flash chromatography (1:5 hexanes/ethyl acetate) gave 37.7 
mg of 3.61 (90%) as colorless oil.
3.61: 1H NMR (500 MHz, CDCb) 5 6.98 (dd, J = 22.0, 17.1 Hz, 1H), 6.10 (dd, J =
20.0, 17.1 Hz, 1H), 6.00 (d, J = 5.9 Hz, 1H), 5.87 (dt, J = 6.4, 2.4 Hz, 1H), 4.89 
(dt, J = 13.7, 1.5 Hz, 1H), 4.78 (dt, J = 13.7, 1.4 Hz, 1H), 4.10 - 4.00 (m, 4H), 
3.74 (s, 3H), 1.29 (t, J = 6.8 Hz, 6H); 13C NMR (125 MHz, CDCb) 5 170.7, 148.4 
(d, J = 6.9 Hz), 128.9, 127.4 (d, J = 2.3 Hz), 117.4 (d, J = 187.7 Hz), 93.1 (d, J =
20.6 Hz), 76.9, 62.2 (d, J = 5.4 Hz), 62.1 (d, J = 5.3 Hz), 53.1, 16.6 (d, J = 6.1 
Hz) ; IR (neat) 2983, 2955, 2866, 1756, 1733, 1632, 1437, 1392, 1251, 1024, 
964 cm-1; LRMS m/z calcd for C12H20O6P 291.1 [M+H]+, found 291.2.
Methyl-E-2-(2-(diethoxyphosphoryl)vinyl)oxetane-2-carboxylate (3.74). To a
solution of iodide 3.26 (30. mg, 0.074 mmol) in acetone (3 mL) at rt was added 





mixture was concentrated. Flash chromatography (1:5 hexane/ethyl acetate) 
gave 12 mg of oxetane 3.74 (56%) as a colorless oil.
3.74: 1H NMR (500 MHz, CDCb) 5 6.95 (dd, J = 21.7, 16.9 Hz, 1H), 6.28 (dd, J = 
19.6, 16.9 Hz, 1H), 4.62 - 4.69 (m, 1H), 4.54 - 4.47 (m, 1H), 4.16 - 4.03 (m, 4H),
3.80 (s, 3H), 3.06 - 2.96 (m, 1H), 2.77 - 2.68 (m, 1H), 1.34 (t, J = 7.3 Hz, 3H),
1.31 (d, J = 7.1 Hz, 3H); 13C NMR (125 MHz, CDCb) 5 171.5, 148.8 (d, J = 6.9 
Hz), 118.0 (d, J = 188.5 Hz), 85.5 (d, J = 21.4 Hz), 66.4, 62.3 (d, J = 5.3 Hz),
62.2 (d, J = 5.3 Hz), 53.1, 32.8 (d, J = 2.3 Hz), 16.6 (d, J = 6.1 Hz), 16.6 (d, J =
5.3 Hz); IR (neat) 2981, 2917, 1756, 1735, 1634, 1438, 1393, 1250, 1107, 1025, 
963 cm-1; LRMS m/z calcd for C11H20O6P 279.1 [M+H]+, found 279.1.
Methyl-E-2-(2-(diethoxyphosphoryl)vinyl)tetrahydrofuran-2-carboxylate 
(3.76). To a solution of bromide 3.27 (24 mg, 0.064 mmol) in acetone (3 mL) at rt 
was added DBU (12 ^L, 0.076 mmol) dropwise. After 4 h the resulting reaction 
mixture was concentrated. Flash chromatography (1:5 hexane/ethyl acetate) 
gave 17 mg of 3.76 (91 %) as a colorless oil.
3.76: 1H NMR (500 MHz, CDCb) 5 6.94 (dd, J = 21.4, 16.6 Hz, 1H), 6.06 (dd, J =
20.0, 17.1 Hz, 1H), 4.10 - 4.01 (m, 6H), 3.74 (s, 3H), 2.36 (ddd, J = 12.7, 7.3, 7.3 
Hz, 1H), 2.05-1.86 (m, 3H), 1.30 (t, J = 6.8 Hz, 3H), 1.29 (t. J = 7.4 Hz, 3H) ; 13C 
NMR (125 MHz, CDCb) 5 172.5, 150.4 (d, J = 6.9 Hz), 116.8 (d, J = 187.7 Hz),




(d, J = 2.3 Hz), 25.1, 16.6 (d, J = 6.1 Hz), 16.5 (d, J = 4.6 Hz); IR (neat) 2982, 
1752, 1732, 1631, 1442, 1392, 1247, 1201, 1093, 1019, 959 cm-1; LRMS m/z 
calcd for C12H22O6P 293.1 [M+H]+, found 293.2.
(2R,3R)-2-(Hydroxymethyl)tetrahydro-2H-pyran-3-ol (3.110). To a solution of 
3.109 (0.189 g, 0.882 mol) in ethyl acetate at rt was added 10% Pd/C (47 mg,
0.044 mmol). The resulting mixture was stirred under H2 (1 atm) for 6 h. The 
reaction mixture was then filtered through a pack of celite and concentrated. The 
crude product was used for the next step without further purification.
The crude mixture from above was dissolved in a 9:6:1 mixture of 
MeOH/H2O/Et3N (8 mL) and stirred for 3h at rt. Concentrate and flash 
chromatography (1: 5 hexane/ethyl acetate) provided 0.106 g of diol 3.110 (91%) 
as a colorless oil.
3.110: [a]D20 = 5.7 (c = 0.85, CHCb) 1H NMR (500 MHz, CDCb) 5 3.98 - 3.96 (m, 
1H), 3.81 (broad s, 1H), 3.75 - 3.70 (m, 2H), 3.57 (broad s, 2H), 3.48 - 3.42 (m, 
1H), 3.34 - 3.32 (m, 1H), 2.88 (broad s, 1H), 2.00 - 1.86 (m, 2H), 1.64 - 1.56 (m, 
1H), 1.34 (broad d, J = 13.0 Hz, 1H); 13C NMR (125 MHz, CDCb) 5 79.4, 68.7,
66.3, 64.0, 30.5, 20.3; IR (neat) 3358 (broad), 2939, 2850, 1650, 1438, 1274, 







(3.107). To a solution of diol 3.110 (0.280 g, 2.12 mmol) and imidazole (0.217 g,
3.18 mmol) in DMF (5 mL) at 0 °C was added TBSCl (0.352 g, 2.33 mmol). The 
resulting reaction mixture was warmed to rt and stirred for an additional 2 h. The 
reaction was quenched with NaHCO3 (aq, 5 mL) and then the resulting mixture 
was diluted with H2O (15 mL). The mixture was extracted with ether (3 x 20 mL) 
and the combined organic extracts were washed with brine (50 mL), dried 
(Na2SO4) and concentrated. The resulting residue was purified using flash 
chromatography (3:1 hexanes/ethyl acetate) to give 0.481g of 3.107 (92%) as a 
colorless oil.
3.107: [a]D20 = -11.5 (c = 1.58, CHCb) 1H NMR (500 MHz, CDCb) 5 4.00 - 3.96 
(m, 1H), 3.88 (broad s, 1H), 3.78 (dd, J = 10.7, 5.8 Hz, 1H), 3.74 (dd, J = 10.2,
4.3 Hz, 1H), 3.45 (ddd, J = 13.7, 11.8, 2.5 Hz, 1H), 3.30 (ddd, J = 5.4, 5.4, 1.0 
Hz, 1H), 2.91 (d, J = 5.5 Hz, 1H), 2.03 - 1.90 (m, 2H), 1.63 - 1.56 (m, 1H), 1.36 -
1.32 (m, 1H), 0.87 (s, 9H), 0.06 (s, 3H), 0.06 (s, 3H); 13C NMR (125 MHz, CDCb) 
5 79.3, 68.8, 65.9, 64.7, 30.5, 26.1, 20.4, 18.5, -5.2, -5.3; IR (neat) 3446 (broad), 
2928, 2855, 1472, 1463, 1252, 1097 cm-1; LRMS m/z calcd for C12H27O3Si 








pyran-3-yl)oxy)-4-(diethoxyphosphoryl)but-2-enoate (3.111). To a solution of 
diazo vinyl phosphonate 3.4 (0.100 g, 0.38 mmol) and alcohol 3.107 (63 mg, 0.26 
mmol) in CH2Cl2 (5 mL) at rt was added Rh2(OAc)4 (1 mg, 0.002 mmol). The 
reaction mixture was concentrated after 10 h. Flash chromatography (1:1 
hexanes/ethyl acetate, SiO2 was neutralized with 1% NEt3) gave 83 mg of 3.111 
(68%) as a colorless oil.
3.111: [a]D20 = -18.3 (c = 1.26, CHCb) 1H NMR (500 MHz, CDCb) 5 6.12 (dt, J = 
7.9, 7.9 Hz, 1H), 4.42 (br, 1H), 4.14 - 4.05 (m, 4H), 4.02 (dd, J = 11.3, 4.9 Hz, 
1H), 3.80 (dd, J = 10.2, 5.9 Hz, 1H), 3.73 (s, 3H), 3.72 (partially obscured dd, J =
11.2, 6.3 Hz, 1H), 3.48-3.42 (m, 2H), 2.96-2.82 (m, 2H), 1.97 - 1.85 (m, 2H), 1.58 
- 1.51 (m, 1H), 1.37 - 1.27 (m, 1H), 1.29 (t, J = 7.1 Hz, 6H), 0.87 (s, 9H), 0.04 (s, 
6H); 13C NMR (125 MHz, CDCb) 5 163.7, 145.8 (d, J = 14.7 Hz), 116.0 (d, J =
11.0 Hz), 80.5, 72.6, 68.2, 63.4, 62.3 (d, J = 5.5 Hz), 62.2 (d, J = 6.1 Hz), 52.1,
27.5, 26.1, 24.5 (d, J = 141.4 Hz), 21.2, 18.6, 16.6 (d, J = 6.1 Hz), -5.1, -5.2; IR 
(neat) 2954, 2929, 2854, 1728, 1647, 1437, 1340, 1253, 1101, 1049, 1027, 965 





2H-pyran-3-yl)oxy)but-2-enoate (3.112). To a solution of 3.111 (221 mg, 0.460 
mmol) in ethanol (10 mL) at rt was added PPTS (127 mg, 0.506 mmol). After 
stirring for 8 h, the reaction mixture was concentrated. Flash chromatography 
(30:1 CH2Cl2/MeOH) gave 124 mg of 3.112 (74%) as a colorless oil.
3.112: [a]D20 = -35.4 (c = 0.68, CHCb) 1H NMR (500 MHz, CDCb) 5 6.20 (dt, J =
7.8, 7.8 Hz, 1H), 4.08 (br, 1H), 4.05 - 3.97 (m, 4H), 3.94 - 3.91 (m, 1H), 3.74 (dd, 
J = 11.2, 7.8 Hz, 1H), 3.67 (s, 3H), 3.56 (dd, J = 11.3, 5.9 Hz, 1H), 3.44 - 3.37 
(m, 2H), 2.82-2.70 (m, 2H), 1.92 - 1.84 (m, 2H), 1.49 - 1.42 (m, 1H), 1.37 - 1.33 
(m, 1H), 1.21 (t, J = 6.6 Hz, 6H); 13C NMR (125 MHz, CDCb) 5 164.4 (d, J = 2.5 
Hz), 145.2 (d, J = 14.0 Hz), 119.1 (d, J = 9.8 Hz), 79.0, 72.8 (d, J = 1.8 Hz), 68.1,
62.3 (d, J = 3.7 Hz), 62.3 (d, J = 3.1 Hz), 61.5, 52.7, 26.4, 24.8 (d, J = 141.6 Hz),
21.4, 16.5 (d, J = 6.1 Hz); IR (neat) 3419 (broad), 2953, 2850, 1723, 1646, 1438, 




Methyl- Z-4- (diethoxyphosphoryl)-2- (((2R,3R)-2- ((tosyloxy) methyl) 
tetrahydro- 2H-pyran-3-yl)oxy)but-2-enoate (3.106). To a solution of 3.112 
(140. mg, 0.382 mmol) NEt3 (80. ^L, 0.57 mmol), and DMAP (5.0 mg, 0.038 
mmol) in CH2Cl2 (5 mL) at 0 °C was added TsCl (80 mg, 0.42 mmol). The 
reaction mixture was allowed to warm to rt and stirred for an additional 6 h. 
Concentration and flash chromatography (1:5 hexanes/ethyl acetate) gave 178 
mg of 3.106 (89%) as a colorless oil.
3.106: [a]D20 = -6.9 (c = 1.17, CHCb) 1H NMR (500 MHz, CDCb) 5 7.78 (d, J =
8.3 Hz, 2H), 7.31 (d, J = 7.8 Hz, 2H), 6.18 (dt, J = 7.8, 7.8 Hz, 1H), 4.42 (dd, J =
11.2, 3.4 Hz, 1H), 4.25 (broad d, J = 1.5 Hz, 1H), 4.15 (dd, J = 11.3, 8.3 Hz, 1H),
4.10 - 4.03 (m, 4H), 3.97 - 3.95 (m, 1H), 3.73 (s, 3H), 3.68 (ddd, J = 7.8, 3.4, 2.0 
Hz, 1H), 3.39 (ddd, J = 12.2, 12.2, 2.0 Hz, 1H), 2.84-2.71 (m, 2H), 2.41 (s, 3H),
1.90 - 1.80 (m, 2H), 1.54 - 1.47 (m, 1H), 1.38 - 1.35 (m, 1H), 1.28 (t, J = 7.1 Hz, 
3H), 1.27 (t, J = 7.1 Hz, 3H); 13C NMR (125 MHz, CDCb) 5 163.4 (d, J = 2.3 Hz),
145.0 (d, J = 14.5 Hz), 144.9, 133.3, 130.0, 128.2, 117.8 (d, J = 10.7 Hz), 77.0, 
72.9 (d, J = 2.3 Hz), 71.0, 67.9, 62.4 (d, J = 3.1 Hz), 62.3 (d, J = 3.8 Hz), 52.3,
26.6, 24.6 (d, J = 141.2 Hz), 21.8, 20.9, 16.6 (d, J = 6.1 Hz); IR (neat) 2957, 
2851, 1724, 1653, 1362, 1253, 1177, 1096, 1048, 1025, 960 cm-1; LRMS m/z 






furo[3,2-6]pyran-2-carboxylate (3.113). To a solution of tosylate 3.106 (150 
mg, 0.286 mmol) and acetone (5 mL) at rt was added DBU (52 ^L, 0.35 mmol) 
dropwise. After stirring for 12 h, the reaction mixture was concentrated. Flash 
chromatography (1:5 hexane/ethyl acetate) gave 85 mg of 3.113 (85%) as a 
colorless oil.
3.113: [a]D20 = 48.6 (c = 2.49, CHCb) 1H NMR (500 MHz, C6D6) 5 7.30 (dd, J =
21.5, 16.6 Hz, 1H), 6.42 (dd, J = 19.6, 17.1 Hz, 1H), 3.98 - 3.85 (m, 4H), 3.78 - 
3.77 (m, 1H), 3.49 - 3.46 (m, 1H), 3.38 (dd, J = 4.4, 2.0 Hz, 1H), 3.20 (s, 3H),
2.81 (ddd, J = 12.7, 12.7, 1.5 Hz, 1H), 2.17 (dd, J = 14.1, 4.9 Hz, 1H), 2.05 (d, J 
= 13.7 Hz, 1H), 1.92 (ddd, J = 14.7, 4.4, 2.0 Hz, 1H), 1.64 (ddddd, J = 26.3, 12.7,
3.9, 3.9 Hz, 1H), 1.22-1.15 (m, 1H), 1.01 (t, J = 7.1 Hz, 3H), 0.97 (t, J = 7.1 Hz, 
3H), 0.82 - 0.77 (m, 1H); 13C NMR (125 MHz, C6D6) 5 172.6 (d, J = 1.5 Hz),
151.4 (d, J = 7.6 Hz), 117.4 (d, J = 187.2 Hz), 84.6 (d, J = 20.6 Hz), 77.9, 76.3,
66.1, 61.4 (d, J = 5.3 Hz), 61.3 (d, J = 6.1 Hz), 51.9, 44.7 (d, J = 2.3 Hz), 24.9,
20.4, 16.3 (d, J = 5.3 Hz); IR (neat) 2925, 2852, 1733, 1635, 1437, 1243, 1104, 
1054, 1022, 964 cm-1; LRMS m/z calcd for C15H26O7P [M+H]+ 349.1, found 349.2.
Summary of 1D NOE data for compound 3.113 (400 Hz, C6D6): 
Irradiation at 1.64 ppm (H-8) resulted in enhancement at 6.42 ppm (H-2); 
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CHAPTER 4
VINYL DIAZO PHOSPHONATES AS PRECURSORS FOR FURANS
4.1 Synthesis of furans bearing a pyrollylindoline scaffold 
In 2010, former group member Dr. Espejo discovered that when treating 3- 
bromoindoline 4.1 with base, cyclopropylazetoindoline 4.2 was formed (Scheme 
4.1).1 This highly strained compound could serve as an efficient and versatile 
electrophile to react with carbon or heteroatom based nucleophiles (Scheme 4.2).
In Chapter 2, we demonstrated that chemo- and stereoselective alkylation of 
phosphonocrotonate 4.9 was viable.2 We envisioned that it would be worthwhile 
to see whether the alkylation of 4.9 with the highly electrophilic 
cyclopropylazetoindoline 4.2 would be possible. To test that, a solution of 4.2 
was added into a premixed THF solution of phosphonocrotonate 4.9 and 
LiHMDS. To our delight, a single product 3.28 was obtained and 1H NMR 
suggested it was the desired mono-alkylation product (Scheme 4.3). The unusual 
chemical shift of the vinyl proton drew our attention. Compared to the other 
alkylated products from 4.9, the chemical shift of the vinyl proton moved 
significantly more upfield (5.5 ppm vs ~6.7 ppm). We suspected that this was due 
to the bulky pyrroloindoline substitution forcing 3.28 to adopt the Z geometry. The 



























Scheme 4.3 Alkylation of phosphonate with cyclopropylazetoindoline
Under standard diazo transfer conditions 4.10 provided diazo 4.11 smoothly 
(Scheme 4.4). Furan 4.12 was obtained when 4.11 was treated with 
Cu(CH3CN)4PF6. We believe that the Z-geometry is necessary for the furan 
formation through the cyclic oxonium ylide intermediate 4.13. Note that in 
Chapter 2, we showed that E-vinyl diazo phosphonates exclusively gave 
cyclopentenes when treating with Rh2(OAc)4.
Scheme 4.4 Synthesis of furan from Z-vinyl diazo phosphonate
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4.2 Synthesis of furans via an E/Z isomerization
We were very excited about the formation of furan 4.12 because furan 
phosphonic acid had been shown to be useful pharmaceuticals.3 In our 
exploration for the synthetic applications of the X-H insertion products, we 
discovered that a second diazo transfer reaction on the O-H insertion product 
such as 4.14 was feasible (Scheme 4.5). When treating diazo 4.15 with 
Rh2(OAc)4 a single product was obtained. To our surprise, the NMR data 
indicated that neither dihydrofuran 4.17 nor the carbene dimer was formed; 
instead, furan 4.16 was obtained. Since NOE experiment clearly showed that in 
the diazo precursor 4.15 the ester group was trans to the diazo functionality, the 
only possible mechanism for the formation of furan 4.16 was by an E/Z alkene 
isomerization (Scheme 4.6). We believe that the enol ether present in 4.15 
facilitated the isomerization.
Mel









Scheme 4.5 Formation of furan from Z- diazo phosphonate
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Scheme 4.6 Proposed mechanism of furan formation
The reaction conditions were further optimized as shown in Table 4.1. The 
catalyst played an important role in this reaction. Rh2(OAc)4 was largely 
deactivated possibly because of substrate binding, and a significant amount of 
starting material (35%) was recovered. Treating diazo 4.15 with copper catalyst 
led to mostly decomposition. More robust catalysts such as Rh2(esp)2 and 
Rh2(Oct)4 gave much better results in terms of yield. The optimal conditions were 
determined to be slowly injection of the diazo compound via a syringe pump into 
a solution of Rh2(Oct)4 catalyst, and the yield of 4.16 was improved to 70% when 
the optimized conditions were applied. Reactions in hexane provided minimal 
amount of product. Thermal conditions failed to provide any desired product 
either, suggesting that the metal carbenoid formation was necessary for the key 
isomerization to happen. To the best of our knowledge, this is the first example 
that furans were synthesized via the E/Z isomerization of vinyl carbenoids.
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Table 4.1 Optimization of furan formation
O _
■■ OEt o
Me° 2CN ^ S ^ P^0 Et .... M e O ^ ° v ^ P ' ° EtI 11 conditions ^C\ if  \ ) E t  
O N , -------------------- ►  \-U
O
.15 4.16
entry catalyst(eq) solvent temp. yield
1 Rh2(OAc)4 (0.02) CH2Cl2 rt 20%
2 Cu(CH3CN)PF6 (0.02) CH2Cl2 rt 15%
3 Rh2(esp)2 (0.02) CH2Cl2 rt 45%
4 none toluene 80oC no rxn.
5 Rh2(OAc)4 (0.02) hexane rt no rxn.
6 Rh2(CF3CO2)4 (0.02) CH2Cl2 rt trace
7 Rh2(Oct)4 (0.02) CH2Cl2 rt 45%
8 Rh2(Oct)4 (0.02) hexane rt trace
9 Rh2(Oct)4 (0.02)a CH2Cl2 rt 62%
10 Rh2(Oct)4 (0.02)b CH2Cl2 rt 70%
a injected with syringe pump in 0.5h 
b injected with syringe pump in 2h
4.3 Conclusion
Furan 4.12 bearing a pyrroloindoline scaffold was successfully synthesized 
from a Z-vinyl diazo phosphonate 4.11. An E/Z isomerization occurred when 
treating diazo 4.15 with a rhodium catalyst and furan 4.16 was formed, which has 
never been documented in literature. Currently, we are exploring the substrate 




NMR spectra were recorded on a Varian Unity-300, Varian Inova-400 or a 
Varian VXR-500 spectrometers. Chemical shifts were reported in 5, parts per 
million (ppm), relative to chloroform (7.25) or dichloromethane (5.29) as internal 
standards. Coupling constants, J, were reported in Hertz (Hz) and refer to 
apparent peak multiplicities and not true coupling constants. Mass spectra were 
recorded at the Mass Spectrometry Facility at the Department of Chemistry of the 
University of Utah at Salt Lake City on a Finnigan MAT 95 mass spectrometer. IR 
spectra were recorded on a Bruker Tensor 27 FT-IR spectrometer. Solvents were 
purified according to the guidelines in Purification of Common Laboratory 
Chemicals (Armarego. W. L. F. and Chai, C. L. L., Oxford, 2009). Spectroscopic 
grade CH3CN was stored over activated 4A molecular sieves and used without 
additional purification. All other reagents were used without purification. Unless 
otherwise stated, all reactions were run under an atmosphere of dried nitrogen in 
flame-dried glassware. Concentration refers to removal of solvent under reduced 
pressure (house vacuum at ca. 20 mmHg).
4.10
(2R,3aS,8aR)-1,8-di-tert-butyl 2-methyl 3a-((Z)-4-(diethoxyphosphoryl)-1 - 
methoxy-1-oxobut-2-en-2-yl)-3,3a-dihydropyrrolo[2,3-b]indole-1,2,8(2H,8aH)
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-tricarboxylate (4.10). To a solution of phosphonocrotonate 4.9 (91 mg, 0.39 
mmol) in THF (5 mL) was added LiHMDS (0.40 mL, 1M solution in THF, 0.40 
mmol) dropwise at 0 oC. After stir for 15 min at 0 oC, a solution of 
cyclopropylazetoindoline 4.2 (0.241 g, 0.579 mmol) in THF (2 mL) was added 
dropwise at 0 oC. The reaction mixture was stirred for 2h at rt and quenched with 
sat. NH4Cl (5 mL). The organic layer was separated and the aqueous layer was 
extracted with ethyl acetate (3^5 mL). The organic layers were combined, dried 
(Na2SO4), and concentrated. Flash chromatography (1:2 hexane/ethyl acetate) 
provided 0.168 g of phosphonate 4.10 (46%) as a colorless oil.
4.10: 1H NMR (300 MHz, CDCb) 5 7.53 (br, 1H), 7.23 - 7.18 (m, 1H), 7.03 - 6.94 
(m, 2H), 6.43 (s, 1H), 5.62 (dt, J = 7.8, 7.8 Hz, 1H), 4.61 (br, 1H), 4.04 - 3.93 (m, 
4H), 3.74 (m, 3H), 3.11 (s, 3H), 3.86 (dd, J = 12.7, 8.1 Hz, 2H), 2.68 - 2.66 (m, 
2H), 1.55 (s, 9H), 1.44 (br, 9H), 1.23 (t, J = 7.1 Hz, 3H), 1.20 (t, J = 7.1 Hz, 3H); 
13C NMR (75 MHz, CDCb) 5 171.8, 167.2 (d, J = 3.5 Hz), 152.4, 143.5, 137.1 (d, 
J = 14.1 Hz), 132.3, 129.9 (d, J = 10.6 Hz), 129.6, 125.0, 123.3, 117.7, 81.7, 81.1 
(d, J = 3.0 Hz), 77.5, 62.4 (d, J = 6.6 Hz), 62.3 (d, J = 6.6 Hz), 59.8, 58.9, 52.1,
38.6, 28.6, 28.5, 28.4 (d, J = 138.0 Hz), 16.6 (d, J = 6.0 Hz); IR (neat) 2979, 1715, 
1481, 1391, 1366, 1252, 1155, 1023, 966 cm-1; LRMS m/z calcd for 





(diethoxyphosphoryl)-1 -methoxy-1 -oxobut-2-en-2-yl)-3,3a- dihydropyrrolo 
[2,3-b]indole-1,2,8(2H,8aH)-tricarboxylate (4.11). To a solution of phosphonate
4.10 (110 mg, 0.169 mmol) and tosyl azide (38 mg, 0.193 mmol) in CH3CN (5 mL) 
was added DBU (30 mg, 0.20 mmol) dropwise at 0 oC. The reaction mixture was 
slowly brought to rt and stirred for 12h. Concentrate and flash chromatography 
(1:1 hexane/ethyl acetate) provided 56 mg of diazo 4.11 (49%) as an orange oil. 
4.11: 1H NMR (500 MHz, CDCb) 5 7.54 (br, 1H), 7.24 - 7.22 (m, 1H), 7.02 - 7.00 
(m, 2H), 6.42 (s, 1H), 5.52 (m, 1H), 4.66 (m, 1H), 4.11 - 3.91 (m, 4H), 3.74 (m, 
3H), 3.12 (s, 3H), 2.79 (dd, J = 12.7, 9.3 Hz, 1H), 2.64 (d, J = 12.7 Hz, 1H), 1.55 
(s, 9H), 1.46 (br, 9H), 1.25 (t, J = 7.3 Hz, 3H), 1.16 (t, J = 6.8 Hz, 3H); 13C NMR 
(75 MHz, CDCls) 5 171.9, 166.3, 152.5, 143.5, 132.4, 129.7, 126.6, 125.2, 124.2,
123.4, 117.9, 81.7, 81.6, 81.1, 77.5, 63.3 (d, J = 5.5 Hz), 59.9, 52.1, 51.9 (d, J =
242.7 Hz), 51.7, 38.8, 28.6, 28.5, 16.3 (d, J = 6.6 Hz), 16.2 (d, J = 7.1 Hz); IR 
(neat) 2979, 2361, 2094, 1760, 1708, 1601, 1392, 1156, 1017 cm-1; LRMS m/z 








(3 mL) at rt was added Cu(CH3CN)4PF6 (1.0 mg, 2.7 ^mol) in one portion. The 
reaction mixture was stirred at rt for 24h. Concentrate and flash chromatography 
(1:2 hexane:ethyl acetate) provided 23 mg of furan 4.12 (64%) as a colorless oil. 
4.12: 1H NMR (300 MHz, CDCb) 5 7.50 (br, 1H), 7.20 (t, J = 6.7 Hz, 1H), 7.07 (d, 
J = 7.6 Hz, 1H), 6.97 (t, J = 7.4 Hz, 1H), 6.76 (br, 1H), 6.28 (br, 1H), 4.60 (br, 1H), 
4.15 - 3.97 (m, 4H), 3.94 (s, 3H), 3.13 (s, 3H), 2.90 - 2.79 (m, 2H), 1.56 (s, 9H), 
1.44 (br, 9H), 1.30 (t, J = 7.1 Hz, 3H), 1.27 (t, J = 7.1 Hz, 3H); 13C NMR (75 MHz, 
CDCb) 5 171.9, 158.8 (d, J = 11.6 Hz), 142.6, 134.2, 132.0 (d, J = 252.8 Hz),
129.1, 125.8 (d, J = 22.2 Hz), 123.9 (d, J = 21.7 Hz), 118.0, 110.1, 100.6, 81.8,
81.7, 81.1, 77.5, 62.9, 59.8, 58.6, 52.1, 37.4, 28.5, 28.5, 16.5 (d, J = 3.5 Hz),
16.4 (d, J = 3.5 Hz); IR (neat) 2979, 1761, 1702, 1623, 1479, 1391, 1152, 1016 
cm-1; LRMS m/z calcd for C31H43N2OnPNa [M+Na]+ 673.3, found 672.9.
(Z)-methyl 2-butoxy-4-diazo-4-(diethoxyphosphoryl)but-2-enoate (4.15). To a
solution of phosphonate 4.14 (0.362 g, 1.17 mmol) and ABSA (0.310 g, 1.29 
mmol) in CH3CN (10 mL) was added DBU (0.214 g, 1.41 mmol) dropwise at 0 oC. 
The reaction mixture was slowly brought to rt and stirred for 12h at rt. 
Concentrate and flash chromatography (2:1 hexane/ethyl acetate) provided
0.312 g of diazo 4.15 (79%) as an orange oil.
4.15: 1H NMR (300 MHz, CDCb) 5 6.07 (d, J = 7.3 Hz, 1H), 4.19 - 4.07 (m, 4H), 
3.83 (t, J = 6 .8  Hz, 2H), 3.74 (s, 3H), 1.65 - 1.60 (m, 2H), 1.41 - 1.33 (partially
4.15
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obscure, m, 2H), 1.34 (t, J = 7.3 Hz, 6H), 0.92 (t, J = 7.3 Hz, 3H); 13C NMR (75 
MHz, CDCb) 5 163.3, 140.3 (d, J = 10.6 Hz), 112.6 (d, J = 12.1 Hz), 63.3 (d, J =
5.5 Hz), 52.0, 49.3 (d, J = 229.1 Hz), 31.3, 19.1, 16.3 (d, J = 7.1 Hz), 14.0; IR 
(neat) 2959, 2874, 2086, 1717, 1618, 1257, 1094, 1018, 971 cm-1; LRMS m/z 
calcd for C13H23N2O6PNa [M+Na]+ 357.3, found 357.2.
Diethyl 4-butoxy-5-methoxyfuran-2-ylphosphonate (4.16). To a solution of 
Rh2(Oct)4 in CH2Cl2 was added a solution of diazo 4.15 in CH2Cl2 via syringe 
pump within 2h at rt. The reaction mixture was stirred for another 2h at rt. 
Concentrate and chromatography (1:1 hexane:ethyl acetate, SiO2 was 
neutralized with 1% NEt3) provided 23 mg of furan 4.16 (70%) as a colorless oil. 
4.16: 1H NMR (300 MHz, CDCb) 57.15 - 7.14 (m, 1H), 4.05 - 3.84 (m, 4H), 3.53 (t, 
J = 6.5 Hz, 2H), 3.42 (s, 3H), 1.39 (quintet, J = 7.0 Hz, 2H), 1.20 (sixtet, J = 7.3 
Hz, 2H), 0.99 (t, J = 7.0 Hz, 6H), 0.73 (t, J = 7.3 Hz, 3H); 13C NMR (100 MHz, 
CDCb) 5 151.5 (d, J = 8.4 Hz), 131.4 (d, J = 249.4 Hz), 125.1 (d, J = 11.5 Hz),
119.3 (d, J = 22.3 Hz), 72.0, 61.9 (d, J = 5.4 Hz), 59.0, 31.4, 18.9, 15.9 (d, J = 6.1 
Hz), 13.5; IR (neat) 2960, 2874, 1751, 1645, 1516, 1257, 1016, 959 cm-1; LRMS 
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APPENDIX
H AND 13C NMR SPECTRA
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